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This publication presents the data and findings of the risk assessment on the new psychoactive 
substance AB-CHMINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-
3-carboxamide), carried out by the extended Scientific Committee of the EMCDDA on 7 and 8 
November 2017.  
The Risk Assessment Report, which was submitted to the European Commission and the Council of 
the European Union on 14 November 2017, examines the health and social risks of the substance, 
information on international trafficking and the involvement of organised crime, as well as a 
consideration of the potential implications of subjecting the substance to control measures. AB-
CHMINACA is the fifteenth new psychoactive substance to be risk assessed under the terms of 
Council Decision 2005/387/JHA. 
On the basis of the Risk Assessment Report on a new psychoactive substance, and, on the initiative 
of the European Commission, the Council may decide that the substance should be subject to control 
measures across the Member States. This decision is adopted in the final stage of the three-step 
process — early warning, risk assessment and control of new psychoactive substances — 
established by the Council Decision 2005/387/JHA. This legal framework allows the EU institutions 
and Member States to act on all new and potentially threatening narcotic and psychotropic drugs 
which appear on the European drug scene, with the EMCDDA and Europol, in collaboration with their 
respective networks, playing a central role in the early detection of such substances as well as the 
harms caused by their use — information that underpins risk assessment, and, ultimately, decision-
making.  
In March 2018, at its 61st regular session, the Commission on Narcotic Drugs (CND) decided to place 
AB-CHMINACA in Schedule II of the Convention on Psychotropic Substances of 1971 based on a 
recommendation by the World Health Organization. This recommendation was substantially 
supported by European data provided by the EMCDDA.  
In this respect we would like to acknowledge the excellent work done by the networks of the 
EMCDDA and Europol, as well as those of the EMA — the Reitox national focal points, Europol 
national units and the national competent authorities responsible for medicinal products — who 
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Finally, we would like to thank all the participants in the risk assessment process for the high quality of 
work carried out. The resulting report is a valuable contribution at European level, which gives clear 
support to political decision-making.  
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The EMCDDA has been assigned a key role in the detection and assessment of new drugs in the 
European Union under the terms of a Council Decision 2005/387/JHA on the information exchange, 
risk-assessment and control of new psychoactive substances. 
It establishes a mechanism for the rapid exchange of information on new psychoactive substances 
and provides for an assessment of the risks associated with them in order to permit the measures 
applicable in the Member States for the control of narcotic and psychotropic substances to be applied 
also to new psychoactive substances. 
The three-step process involves information exchange/early warning, risk assessment and decision-
making (see below). More detailed information can be found in the section ‘Action on new drugs’ of 
the EMCDDA’s website: www.emcdda.europa.eu/activities/action-on-new-drugs  
 
  
EMCDDA actions on monitoring and responding to 
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Europol–EMCDDA Joint Report on a new psychoactive substance: N-(1-amino-3-methyl-1-
oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide — in accordance with Article 
5 of Council Decision 2005/387/JHA on the information exchange, risk assessment and control 
of new psychoactive substances 
In March 2017, the EMCDDA and Europol examined the available information on a new psychoactive 
substance N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide, 
commonly known by the abbreviation ‘AB-CHMINACA’, through a joint assessment based upon the 
following criteria: (1) the amount of the material seized; (2) evidence of organised crime involvement; 
(3) evidence of international trafficking; (4) analogy with better-studied compounds; (5) evidence of 
the potential for further (rapid) spread; and (6) evidence of cases of serious intoxication or fatalities. 
The EMCDDA and Europol agreed that the information available on AB-CHMINACA satisfied criteria 
1, 4 and 6. The two organisations therefore concluded that sufficient information has been 
accumulated to merit the production of a Joint Report on AB-CHMINACA as stipulated by Article 5.1 
of the Decision. Accordingly, the NFPs, the Europol national units (ENUs), the EMA and the World 
Health Organization (WHO) were formally asked to provide the relevant information within six weeks 
from the date of the request, i.e. by 6 June 2017. 
The resulting Joint Report on AB-CHMINACA was submitted to the Council, the Commission and the 
EMA on 3 July 2017. The report concluded that the health and social risks, caused by the use of, the 
manufacture of, and traffic in AB-CHMINACA, as well as the involvement of organised crime and 
possible consequences of control measures, could be thoroughly assessed through a risk 
assessment procedure as foreseen by Article 6 of Council Decision 2005/387/JHA. 
The full text of the Joint Report can be found at: 
www.emcdda.europa.eu/publications/joint-reports/ab-chminaca 
  
Europol–EMCDDA Joint Report on N-(1-amino-3-
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Introduction  
This Risk Assessment Report presents the summary findings and the conclusion of the risk 
assessment carried out by the extended Scientific Committee of the European Monitoring Centre for 
Drugs and Drug Addiction (EMCDDA) on the new psychoactive substance N-(1-amino-3-methyl-1-
oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (commonly known as AB-
CHMINACA). The report is intended for policy makers and decision makers in the institutions of the 
European Union. 
The report has been prepared and drafted in accordance with the conceptual framework and the 
procedure set out in the risk assessment operating guidelines (1). It is written as a stand-alone 
document, which presents a summary of the information considered during the detailed analysis of 
the scientific and law enforcement data available at this time. The conclusion section of the report 
summarises the main issues addressed and reflects the opinions held by the members of the 
Scientific Committee. A list of the information resources considered by the Scientific Committee, 
including a detailed technical report on AB-CHMINACA, is provided below.  
The risk assessment has been undertaken in compliance with Article 6 of Council Decision 
2005/387/JHA of 10 May 2005 on the information exchange, risk assessment and control of new 
psychoactive substances (2) (hereafter ‘Council Decision’). The Council Decision establishes a 
mechanism for the rapid exchange of information on new psychoactive substances (hereafter ‘EU 
Early Warning System’ (3)) that may pose public health and social threats, including those related to 
the involvement of organised crime. Thus, it allows the institutions of the European Union and the 
Member States to act on all new narcotic and psychotropic substances (4) that appear on the 
European Union drug market. The Council Decision also provides for an assessment of the risks 
                                                          
(1)  EMCDDA (2010), Risk assessment of new psychoactive substances: Operating guidelines, Publications Office of the 
European Union, Luxembourg. Available at: http://www.emcdda.europa.eu/html.cfm/index100978EN.html 
(2) OJ L 127, 20.5.2005, p. 32. 
(3) The information exchange mechanism laid down by the Council Decision is operationalized as the European Union 
Early Warning System on New Psychoactive Substances (‘EU Early Warning System’). It is operated by the 
EMCDDA and Europol in partnership with the Reitox national focal points and Europol national units in the Member 
States, the European Commission, and the European Medicines Agency. 
(4) According to the definition provided by the Council Decision, a ‘new psychoactive substance’ means a new narcotic 
drug or a new psychotropic drug in pure form or in a preparation; ‘new narcotic drug’ means a substance in pure form 
or in a preparation that has not been scheduled under the 1961 United Nations Single Convention on Narcotic Drugs, 
and that may pose a threat to public health comparable to the substances listed in Schedule I, II or IV; ‘new 
psychotropic drug’ means a substance in pure form or in a preparation that has not been scheduled under the 1971 
United Nations Convention on Psychotropic Substances, and that may pose a threat to public health comparable to 
the substances listed in Schedule I, II, III or IV. 
Risk Assessment Report on a new psychoactive 
substance: N-(1-Amino-3-methyl-1-oxobutan-2-yl)-
1-(cyclohexylmethyl)-1H-indazole-3-carboxamide  
(AB-CHMINACA) 
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associated with these new psychoactive substances so that, if necessary, control measures can be 
applied in the Member States for narcotic and psychotropic substances (5). 
AB-CHMINACA was formally notified on 10 April 2014 by the EMCDDA on behalf of the Latvian 
national focal point, in accordance with Article 4 of the Council Decision. The notification related to the 
seizure of 8 bags of herbal material with a total weight of 3.81 grams seized in February 2014 by 
police. Following an assessment of the available information on AB-CHMINACA, and, in accordance 
with Article 5 of the Council Decision, on 3 July 2017 the EMCDDA and Europol submitted a Joint 
Report on AB-CHMINACA (6) to the Council of the European Union, the European Commission, and 
the European Medicines Agency (EMA). Taking into account the conclusion of the Joint Report, and, 
in accordance with Article 6 of the Council Decision, on 14 September 2017 the Council formally 
requested that ‘the risk assessment should be carried out by the extended Scientific Committee of the 
EMCDDA and be submitted to the Commission and the Council within twelve weeks from the date of 
this notification’. 
In accordance with Article 6.2, the meeting to assess the risks of AB-CHMINACA was convened 
under the auspices of the Scientific Committee of the EMCDDA with the participation of four additional 
experts designated by the Director of the EMCDDA, acting on the advice of the Chairperson of the 
Scientific Committee, chosen from a panel proposed by Member States and approved by the 
Management Board of the EMCDDA. The additional experts were from scientific fields that were 
either not represented, or not sufficiently represented on the Scientific Committee, and whose 
contribution was necessary for a balanced and adequate assessment of the possible risks of AB-
CHMINACA, including health and social risks. A further four experts participated in the risk 
assessment: two experts from the Commission, one expert from Europol, and one expert from the 
European Medicines Agency (EMA). The meeting took place on 7 and 8 November 2017 at the 
EMCDDA in Lisbon. The risk assessment was carried out on the basis of information provided to the 
Scientific Committee by the Member States, the EMCDDA, Europol and the EMA. A list of the 
extended Scientific Committee, as well as the list of other participants attending the risk assessment 
meeting, is annexed to this report (page 65). 
For the risk assessment, the extended Scientific Committee considered the following information 
resources: 
i. Technical report on N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-
3-carboxamide (AB-CHMINACA) (Annex 1); 
ii. EMCDDA–Europol Joint Report on a new psychoactive substance: N-(1-amino-3-methyl-1-
oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA) (6); 
iii. Open source information including scientific articles, official reports, grey literature, internet 
drug discussion forums and related websites (hereafter ‘user websites’); 
iv. Additional information provided during the course of the risk assessment meeting by the 
participants; 
v. The EMCDDA operating guidelines for the risk assessment of new psychoactive substances 
(1); and, 
                                                          
(5) In compliance with the provisions of the United Nations Single Convention on Narcotic Drugs, 1961, and the United 
Nations Convention on Psychotropic Substances, 1971. 
(6) EMCDDA (2017), EMCDDA–Europol Joint Report on a new psychoactive substance N-(1-amino-3-methyl-1-
oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA), EMCDDA, Lisbon. Available at: 
http://emcdda.europa.eu/publications/joint-reports/ab-chminaca 
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vi. Council Decision 2005/387/JHA of 10 May 2005 on the information exchange, risk 
assessment and control of new psychoactive substances (2). 
Finally, it is important to note that this risk assessment report contains a discussion of the available 
information on serious adverse events such as acute intoxications (typically presenting to hospital 
emergency departments) and deaths associated with AB-CHMINACA. Such information is critical to 
the identification of emerging toxicological problems associated with new psychoactive substances 
within the European Union. In this context, it is important to recognise that the capacity to detect, 
identify, and report these events differ both within and between Member States. In the past few years, 
programmes have been introduced in some Member States to strengthen these capacities. The 
EMCDDA’s toxicovigilance system, which is a central component of the EU Early Warning System, 
has also been strengthened resulting in more information being available regarding serious adverse 
events associated with new psychoactive substances. Nonetheless, it is likely that these events 
remain under-detected and under-reported.  
Physical, chemical and pharmacological description 
N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide, also known 
as AB-CHMINACA, is an indazole-based synthetic cannabinoid receptor agonist (synthetic 
cannabinoid). The common name for the substance is derived after its structural features (7): a methyl 
amino butanone linked group (AB), a cyclohexylmethyl tail (CHM), an indazole core (INA) and a 
carboxamide linker (CA).  
AB-CHMINACA contains a stereogenic centre and therefore two possible enantiomers may exist, (R)- 
and (S)-AB-CHMINACA. (S)-AB-CHMINACA was originally described in a patent application by Pfizer 
Inc., and published in 2009. No information is available on whether the AB-CHMINACA detected in 
the European drug market corresponds to the (R)- or (S)- enantiomer, or a mixture of both. Based on 
the literature and the precursors that are most likely to be used, an (S)-configuration of the 
stereocentre could be expected. 
Synthetic cannabinoids such as AB-CHMINACA are functionally similar to Δ9-tetrahydrocannabinol 
(THC), the major psychoactive principle of cannabis. Like THC, they bind to and activate the CB1 and 
CB2 cannabinoid receptors which form part of the endocannabinoid system — a system that helps 
regulate a large number of physiological functions in the body such as behaviour, mood, pain, 
appetite, sleep, the immune system, and the cardiovascular system. Many synthetic cannabinoids 
were first developed to study the endocannabinoid system as well as to explore their potential as 
therapeutic agents to treat a number of diseases and their symptoms (such as neurodegenerative 
diseases, drug dependence, pain disorders, and cancer). 
Since around 2006, ‘legal high’ products containing synthetic cannabinoids have been sold in Europe 
as ‘herbal smoking mixtures’ and marketed as ‘legal’ replacements for cannabis. These products are 
made by dissolving the synthetic cannabinoids in solvents such as acetone or methanol and then 
mixing them with, or, spraying them on, plant material such as the herbs Damiana (Turnera diffusa) 
and Lamiaceae (such as Melissa, Mentha and Thymus). Such products are generally referred to by a 
variety of names in Europe, including ‘Spice’ (8), ‘herbal smoking mixtures’, ‘herbal incense’, and 
‘synthetic cannabis’. Manufacturers of smoking mixtures frequently change the synthetic cannabinoids 
                                                          
(7)  Different naming systems exist and are used for applying short/code names to synthetic cannabinoids. 
http://www.emcdda.europa.eu/topics/pods/synthetic-cannabinoids 
(8) Which is a reference to the most common brand name used for these types of products when they first appeared on 
the European market. 
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in the products, which means that product names are not a reliable source of information regarding 
the actual substances that are present. Almost 180 synthetic cannabinoids, in hundreds of different 
products, have been identified on the European drug market since 2008. They are the largest group 
of substances that are monitored by the EMCDDA through the EU Early Warning System. 
A number of cannabinoids are controlled under the United Nations Convention on Psychotropic 
Substances, 1971 (Schedule II). These are: the major active principle of cannabis, delta-9-
tetrahydrocannabinol (Δ9-THC) (9), as well as the synthetic cannabinoids JWH-018 (10), AM-2201 (11), 
MDMB-CHMICA (12), 5F-APINACA (5F-AKB-48) (13), and XLR-11 (14).  
In its pure form AB-CHMINACA has been described as a white to off-white crystalline powder. It is 
poorly soluble in water. 
Information provided from seizures and collected samples reported to the EMCDDA have noted that 
AB-CHMINACA is typically found in herbal/plant material (including as commercially-branded ‘legal 
high’ products) and as a powder. To a lesser extent, other forms, such as liquids and blotters, have 
also been reported. 
The analytical identification of AB-CHMINACA in physical and biological samples is possible using 
standard analytical techniques. These include chromatographic and mass spectrometric methods.  
Analytical reference material is important for correct identification and for facilitating the quantification 
of AB-CHMINACA in physical and biological samples. Such material is commercially available.  
Route of administration and dosage 
The most common way of using synthetic cannabinoids such as AB-CHMINACA is by smoking either 
ready-to-use or homemade ‘smoking mixtures’ as a cigarette (‘joint’) or by using a vaporizer, ‘bong’, 
or pipe. Some synthetic cannabinoids, including AB-CHMINACA, have also been offered in the form 
of e-liquids for vaping in e-cigarettes. Additionally, users might also prepare AB-CHMINACA 
containing e-liquids at home. To a lesser extent, other routes of administration for synthetic 
cannabinoids have been reported; these include oral and rectal. 
Limited information is available regarding the dose and the dose regimens of AB-CHMINACA. User 
reports specifically about AB-CHMINACA were not particularly revealing. It is not possible to discern 
the ‘typical’ dosages administered as most individuals use herbal smoking mixtures. Nonetheless, 
based on data from the analysis of some of these products, a gram of herbal material could contain 
more than 100 mg of AB-CHMINACA (and potentially other synthetic cannabinoids). These 
compounds may be active at less than 1 mg.  
 
 
                                                          
(9) Including some of its named isomers and their stereochemical variants. 
(10) JWH-018: naphthalen-1-yl(1-pentyl-1H-indol-3-yl)methanone. 
(11) AM-2201: 1-(5-fluoropentyl)-1H-indol-3-yl]-(naphthalen-1-yl)-methanone. 
(12) MDMB-CHMICA: methyl (2S)-2-{[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]amino-3,3-dimethylbutanoate. MDMB-
CHMICA was risk assessed by the Scientific Committee of the EMCDDA in July 2016. 
(13) 5F-APINACA: N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide.  
(14) XLR-11: [1-(5-fluoropentyl)-1H-indole-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone.  
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Pharmacology 
Data on the pharmacodynamic effects of AB-CHMINACA show that it is a potent and full agonist at 
the CB1 receptor (i.e. activates the receptor) of the endocannabinoid system. These data show that 
AB-CHMINACA is 4 times more potent than JWH-018, which is a full agonist under international 
control. In addition, AB-CHMINACA can produce cannabinoid/THC-like effects at doses much lower 
than THC, which is a partial agonist. So far AB-CHMINACA has been identified as a partial agonist at 
the CB2 receptor.  
Data on the pharmacokinetics of AB-CHMINACA are limited to the identification of metabolites. So 
far, over 10 metabolites have been identified in humans. The pharmacological effects of these 
metabolites have not been investigated. 
No studies were identified that have investigated the pharmacodynamics of AB-CHMINACA on other 
pharmacological targets. 
Information from self-reported user experiences on the Internet have described an onset time of 1 to 5 
minutes after smoking with duration of the effect for 1 to 2 hours. The assessment of such reports is 
problematic not least because users cannot confirm the actual substance or the amount used. In 
general, given the difficulties of collecting accurate self-reported data, it should be interpreted with 
caution. 
Interactions with other substances, medicines, and other forms of interactions 
No studies were identified that have investigated the potential interactions of AB-CHMINACA. 
Psychological and behavioural effects 
While there is limited data, the psychological and behavioural effects of AB-CHMINACA appear to 
share some similarities with cannabis, THC, and other synthetic cannabinoids. This includes: 
relaxation, euphoria, lethargy, confusion, anxiety, and fear, distorted perception of time, 
depersonalisation, hallucinations, paranoia, as well as dry mouth, bloodshot eyes, tachycardia, 
nausea, vomiting, and impaired motor performance. These effects appear to be much more 
pronounced and severe when compared to cannabis. In addition, psychotic episodes, as well as 
aggressive and violent behaviour, have also been reported. 
Legitimate uses 
AB-CHMINACA is used as an analytical reference material in clinical and forensic case 
work/investigations as well as scientific research. There is currently no information that suggests AB-
CHMINACA is used for other legitimate purposes. 
There are no reported uses of AB-CHMINACA as a component in industrial, cosmetic, or agricultural 
products. In addition, a search of the Registration, Evaluation, Authorisation and Restriction of 
Chemicals (REACH) registered substances database hosted by the European Chemicals Agency 
(ECHA) using the available CAS Registry Numbers returned no hits. 
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There is no marketing authorisation (existing, on-going, or suspended) for AB-CHMINACA in the 
European Union or in the Member States that responded to the request for information, that was 
undertaken as part of the Joint Report process (6). 
There is no information to suggest that AB-CHMINACA is currently used in the manufacture of a 
medicinal product in the European Union (6). However, in the absence of a database on the synthetic 
routes of all medicinal products it is not possible to confirm whether or not AB-CHMINACA is currently 
used in the manufacture of a medicinal product. 
Chemical precursors that are used for the manufacture 
The chemical precursors and the synthetic routes used to manufacture AB-CHMINACA are known 
from the literature. The potential precursors of AB-CHMINACA are: 1H-indole-2,3-dione, 1H-indazole-
3-carboxylic acid, methyl or other alkyl1H-indazole-3-carboxylic acid esters, L-valinamide (for 
synthesis of the (S)-enantiomer), and (bromomethyl)cyclohexane. Some of these are commercially 
available. It is important to note that L-valinamide is derived from inexpensive natural sources or 
produced by industrial fermentation. Since this reagent is used for the synthesis of the (S)-
enantiomer, it can be speculated that this will be the form of AB-CHMINACA most likely to be 
encountered on the European market. 
Commercially available domestic or industrial products which could be used for synthesis of AB-
CHMINACA may contain potentially toxic substances, including heavy metals and organic solvents. 
Use of such products as reagents may result in serious toxic effects if the resultant impure product is 
consumed. The herbal material which is used as a basis for smoking mixtures may also contain 
toxicologically relevant substances (such as pesticides that could potentially be present in the plant 
material). 
Health risks 
Individual health risks 
The assessment of individual health risks includes consideration of the acute and chronic toxicity of 
AB-CHMINACA, as well as its abuse liability and dependence potential. Similarities to, and, 
differences from, other chemically or pharmacologically related substances should also be 
considered. 
It is important to note that when interpreting information from acute intoxications and deaths as well 
as information from user websites, individuals may have used other pharmacologically active 
substances in addition to AB-CHMINACA. The presence of and/or interaction with other substances 
or pre-existing health conditions may account for some of the effects reported. 
Some individuals may use AB-CHMINACA in combination with other drugs (either intentionally or 
unintentionally). AB-CHMINACA is typically encountered in combination with other substances in 
commercially branded ‘legal high’ products, and, in particular, with other synthetic cannabinoids. 
Analyses of various seized products have shown that the composition can vary significantly over 
geographical areas and time. Therefore, the users are unlikely to be aware of the substance(s) being 
ingested and doses used (by whatever route). This presents an inherent risk to the individual. 
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As synthetic cannabinoids such as AB-CHMINACA mimic the effects of THC, their effects appear to 
have some similarities with cannabis. This includes: relaxation, euphoria, lethargy, confusion, anxiety, 
and fear, distorted perception of time, depersonalisation, hallucinations, paranoia, as well as dry 
mouth, bloodshot eyes, tachycardia, nausea, vomiting, and impaired motor performance. In some 
cases, these effects appear to be much more pronounced and severe when compared to cannabis.  
Severe and fatal poisonings have occurred with synthetic cannabinoids. This can include severe 
cardiovascular toxicity (including sudden death), severe central nervous system depression (such as 
rapid loss of consciousness/coma), respiratory depression, seizures and convulsions, hyperemesis, 
delirium, agitation, psychotic episodes, and aggressive and violent behaviour. 
In addition, some of the features of poisoning—particularly loss of consciousness, respiratory 
depression, and behavioural effects—may place users at additional risks, such as choking 
on/aspirating vomit, drowning, falling, hypothermia as a result of falling unconscious outside in cold 
weather, and self-inflicted violence/injury. The aggressive and violent behaviours reported with 
synthetic cannabinoids may also place others at risk of injury. 
The reasons for these more pronounced and severe effects, as well as severe and fatal poisoning, 
are poorly understood, but at least two factors are likely to be important: the high potency of the 
substances and the unintentionally high doses that users are exposed to. 
Firstly, studies have found that many of the synthetic cannabinoids, including AB-CHMINACA, which 
are sold on the drug market, are much more potent and active, typically behaving as full agonist as 
compared to THC. This means that even at very small doses they can activate the CB1 receptor much 
more strongly than THC.  
Secondly, the process for making smoking mixtures (which are the most common way of using these 
substances) can lead to dangerous amounts of the substances in the products. This is because 
producers have to guess the amount of cannabinoids(s) to add, while the mixing process makes it 
difficult to dilute the substances sufficiently and distribute them consistently throughout the plant 
material. This can result both in products that contain toxic amounts of the substances in general, as 
well as products where the cannabinoids are clumped together forming highly concentrated pockets 
within the plant material. These issues are made worse as the products are typically smoked allowing 
the substances to be rapidly absorbed into the systemic circulation (bloodstream) and to reach the 
brain. 
The combination of these two factors makes it difficult for users to control the dose that they are 
exposed to and can lead them to rapidly administer a toxic dose unintentionally. Accounts from 
patients and people who witness poisonings involving smoking mixtures suggest that in some cases a 
small number of puffs from a cigarette have been sufficient to cause severe and fatal acute poisoning.  
Currently there is no approved antidote to poisoning caused by synthetic cannabinoids. 
Overall, poisoning with synthetic cannabinoids may be made worse when other drugs, especially 
central nervous system depressants (such as alcohol, opioids, and sedative/hypnotics), are used at 
the same time. 
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Acute toxicity 
The acute toxicity of AB-CHMINACA and/or its metabolites have not been studied in non-clinical and 
clinical studies. In addition to the acute intoxications and deaths reported to the EMCDDA (discussed 
below), cases of acute intoxications and deaths have also been reported in the literature. In general, 
the available data suggests that intoxication/poisoning with AB-CHMINACA appears to be similar to 
other synthetic cannabinoids. 
Acute intoxications 
A total of 7 acute intoxications with confirmed exposure to AB-CHMINACA were reported to the 
EMCDDA by Belgium (1 case), France (1), Hungary (3), and the United Kingdom (2). The cases 
occurred between 2014 and 2016. No further details are available on the cases from Hungary.  
In 2 out of the remaining 4 cases, no other substances were detected. In the other 2 cases other 
substances detected included synthetic cannabinoids and an opioid. In all 4 cases, the clinical 
features of poisoning appeared to be similar to those reported for other synthetic cannabinoids. 
Deaths 
A total of 31 deaths with confirmed exposure to AB-CHMINACA were reported to the EMCDDA by 
Croatia (1 case), Germany (4), Hungary (11), Poland (2), Sweden (5), and the United Kingdom (8). In 
all cases, exposure to AB-CHMINACA (or an associated metabolite in one case) was analytically 
confirmed from post-mortem samples.  
The deaths occurred between 2014 and 2017. Demographic data were available for all but 6 deaths 
and involved 24 males (77%) and 1 female (3%). The mean age of the males was 30 years (median 
27) and ranged from 16 to 66 years. The female was 38 years old. 
Cause of death and toxicological significance 
A cause of death was reported in 22 cases, and, in at least 9 deaths, AB-CHMINACA was either the 
cause of death or is likely to have contributed to death (even in presence of other substances); other 
substances were detected in 25 cases. AB-CHMINACA was the only drug present in 6 deaths based 
on additional toxicological information, where available. 
AB-CHMINACA was quantified in 11 cases. Post-mortem blood concentrations between 0.32 and 12 
ng/mL (median 3.70 ng/mL), or equivalent, were recorded. However, post-mortem blood 
concentrations cannot necessarily be used to determine a “fatal” concentration. In the majority of 
circumstances involving synthetic cannabinoids, the mere presence of the drug is of significance 
whether concentration has been determined or not, especially in situations of poly-drug use and the 
varying circumstances in which they are used. 
A range of other substances were detected in the deaths, including: alcohol, cannabinoids, 
antidepressants, antipsychotics, cocaine, zopiclone, synthetic cathinones, opiates/opioids (morphine, 
buprenorphine, acetylfentanyl, tramadol, methadone, codeine) and benzodiazepines. Other synthetic 
cannabinoids and/or metabolites were detected in 6 of the deaths, including: MDMB-CHMICA, 5F-
MDMB-PINACA, ADB-CHMINACA, FUB-AKB-48, 5F-PB-22, and UR-144. 
Overall, while other substances may have contributed some toxicity, the potent nature of AB-
CHMINACA means the primary toxic contribution could be attributed to the drug and death may not 
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have occurred if AB-CHMINACA had not been used. However, in the cases where multiple synthetic 
cannabinoids were present, it is not necessarily possible or appropriate to identify AB-CHMINACA as 
the primary synthetic cannabinoid that may have produced toxicity, but a synergistic effect is likely 
nonetheless. Sufficient case data were available in 29 of the 31 deaths. An assessment of the 
toxicological significance score (TSS) (15) incorporating the above considerations in the deaths, 
showed that AB-CHMINACA had a TSS value of 3 (high) in 18 deaths (where it was cited as the 
cause of death or is likely to have contributed to death following assessment). In the remaining 11 
deaths, there was an alternative cause of death (such as hanging, drowning, stabbing, other drug 
overdose, or other physiological cause) (TSS value of 1, low). However, there is a possibility that use 
of AB-CHMINACA could have contributed to some of these situations/causes but there was 
insufficient circumstance and other information to allow this attribution. 
Circumstances of death 
There was a lack of information regarding any symptoms experienced by the deceased prior to death 
in the majority of cases, but, in one case, the deceased was described to have vomited and became 
hypothermic and unconscious. Where information was known, in the majority of instances the 
individuals were found dead, predominantly in a home environment (either their own or a friend’s), or 
outside; 2 of the deaths occurred in prison. Consequently, it was not possible to identify or evaluate 
ante-mortem symptoms (especially in relation to acute intoxication) in these cases. 
Ability to operate machinery and drive 
No studies of the effects of AB-CHMINACA on the ability to drive and operate machines have been 
performed. However, it is has been reported that intoxications caused by a range of synthetic 
cannabinoids, including AB-CHMINACA, significantly impair the mental and physical ability that is 
required to drive and operate machines. 
Chronic toxicity 
No studies were identified that investigated the chronic health effects of AB-CHMINACA and/or its 
metabolites.  
Abuse liability and dependence potential 
There have been no studies that have investigated the abuse liability and dependence potential of 
AB-CHMINACA. Given what is currently known about the pharmacology of AB-CHMINACA, including 
some similarities to THC, it is reasonable to consider that the substance may have both a potential for 
abuse and dependence. Further research will be required in order to determine such effects. 
Public health risks 
The public health risks associated with AB-CHMINACA may be categorised in terms of patterns of 
use (extent, frequency, route of administration, etc.); availability and quality of the drug; information, 
availability, and levels of knowledge amongst users; and, negative health consequences. Detailed 
information, including data on sporadic versus chronic use, that allow for a determination of public 
health risks associated with AB-CHMINACA are unavailable.  
                                                          
(15) Elliott, S., Sedefov, R. and Evans-Brown, M. (2017), 'Assessing the toxicological significance of new psychoactive 
substances in fatalities', Drug Testing and Analysis. https://doi.org/10.1002/dta.2225 
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Extent, frequency, and patterns of use 
The available data suggest that AB-CHMINACA is typically sold as commercial branded ‘legal high’ 
smoking mixtures in head shops as well as on the Internet as ‘legal’ replacements for cannabis. It 
may also be sold directly on the illicit drug market. Overall, the available information does not suggest 
widespread use of the substance. 
No surveys were identified that have investigated the prevalence of AB-CHMINACA use in the 
general population or in specific user groups. 
Because of the variability in the composition of smoking mixtures, and the fact that the ingredients are 
not typically disclosed, most users will be unaware that they are using AB-CHMINACA. As a result, 
the prevalence of use should be considered in the wider context of the prevalence of use of herbal 
smoking mixtures (sometimes referred to as ‘spice’). 
The use of herbal smoking mixtures has been studied in some European countries in general 
population surveys and in specific populations such as students, ‘clubbers’ and/or internet users. The 
results of these surveys are not comparable as they use different methodology and samples, but, 
overall, they indicate generally low prevalence levels in these groups. 
It is reasonable to assume that AB-CHMINACA may be sought by those looking for ‘legal’ substitutes 
for cannabis. This includes individuals subject to drug testing (such as drivers, prisoners, those in 
drug treatment, and those subject to workplace drug testing), as commonly used drug tests may be 
unable to detect the compounds. 
In addition, reports suggest that in some areas, high risk drug users and other vulnerable groups, 
such as the homeless and prisoners, may specifically seek out synthetic cannabinoids because they 
have a reputation for causing profound intoxication, they can be cheap, and are easy to smuggle. 
Availability and quality on the market 
Since February 2014, when it was detected first in Latvia, AB-CHMINACA has been detected in a 
total of 24 Member States, as well as Turkey and Norway. As the substance is not routinely screened 
for, detections of AB-CHMINACA may be under-reported. 
AB-CHMINACA is sold online either as commercial ‘legal high’ smoking mixtures or as a powder. The 
presence of AB-CHMINACA (or any other synthetic cannabinoid) is not typically disclosed on the 
packaging/advertising of smoking mixtures. 
Due to the high potency of some synthetic cannabinoids, the amount of powder needed for each 
packet can be in the order of tens of milligrams. This means that each kilogram of bulk powder may 
produce thousands of packets of ‘legal highs’ (Section 6).  
Detailed information with regards to route-specific by-products produced during the synthesis of AB-
CHMINACA is not available. Quantitative information on the AB-CHMINACA in the seized samples is 
limited. In herbal material, AB-CHMINACA was frequently found with other substances, and, in 
particular, synthetic cannabinoids. 
As discussed above, in general, smoking mixtures appear to pose a high risk of poisoning/acute 
toxicity because of the high potency of synthetic cannabinoids, the manufacturing process used, and 
the route of administration.  
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Characteristics and behaviour of users 
Information on the characteristics and behaviour of users of AB-CHMINACA is limited.  
‘Legal high’ products containing AB-CHMINACA are marketed as ‘legal’ replacements to cannabis. It 
is therefore likely that a range of different cannabis users would be interested in these products. The 
available data suggests that AB-CHMINACA is used by cannabis users, including those who are 
regularly subjected to drug testing procedures. To a lesser degree it is also used by psychonaut-type 
users. 
In addition, and, of particular note, is that in some settings, synthetic cannabinoids are increasingly 
used by high risk drug users and other vulnerable groups, such as the homeless and prisoners. In at 
least some cases, these users are specifically seeking out synthetic cannabinoids because the 
substances have developed a reputation for causing profound intoxication, they can be cheap, and 
are easy to smuggle. 
In most cases, it appears that AB-CHMINACA is not specifically sought after by users who will 
typically purchase it unknowingly as part of a smoking mixture product. 
Nature and extent of health consequences 
Information on the nature and extent of health consequences are mostly limited to those discussed in 
relation to individual health risks. 
The high potency of the synthetic cannabinoids, coupled to the unintentionally high doses that users 
are exposed to, is also responsible for outbreaks of mass poisonings involving smoking mixtures. 
Such outbreaks have ranged in size from four or five to over 800 victims, including deaths. While 
many of the outbreaks that have been reported so far are from the United States, they have also 
occurred in Russia and Europe. AB-CHMINACA has been involved in a number of outbreaks in the 
United States. Mass poisonings can rapidly overwhelm emergency responders and other local 
healthcare systems. 
Unknown to users, synthetic cannabinoids have also been sold as ecstasy/MDMA and other illicit 
drugs. In some cases, this has led to severe poisoning. Opioids have also been identified in smoking 
mixtures. While the overall number of detections appears to be relatively small, it could pose a risk of 
severe opioid poisoning, including life-threatening respiratory depression especially in individuals with 
no tolerance to opioids. Users of smoking mixtures will be unaware of this risk. 
Long-term consequences of use 
While there is limited data for AB-CHMINACA, the long-term consequences of use might share 
similarities to cannabis and other synthetic cannabinoids. This may include dependence. 
Conditions under which the substance is obtained and used 
There is limited data on the conditions under which AB-CHMINACA is obtained and used. Sources 
appear to include internet retailers, physical shops, friends and other acquaintances, and street-level 
drug dealers. As highlighted, most users will be unaware that they have sourced and used AB-
CHMINACA as they will be using smoking mixtures. The available data suggests that AB-CHMINACA 
is used in similar environments to cannabis, including the home, other recreational settings, and 
prisons. 
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Social risks  
The available data suggests that the acute behavioural effects of AB-CHMINACA bear some 
similarities to cannabis but are more pronounced and severe. 
In addition, and, of particular note, is that in some settings, synthetic cannabinoids are increasingly 
used by high risk drug users and other vulnerable groups, such as the homeless and prisoners. In at 
least some cases, these users are specifically seeking out synthetic cannabinoids because the 
substances have developed a reputation for causing profound intoxication, they can be cheap and are 
easy to smuggle. Reports suggest that this has exacerbated existing health and social problems for 
these vulnerable groups, as well as creating new ones.  
Individual social risks 
While there is no specific information on whether the use of AB-CHMINACA causes individual social 
risks, any such risks may have some similarities with those associated with cannabis and other 
synthetic cannabinoids. These may impact on education or career, family or other personal and social 
relationships, and may result in marginalisation. 
Possible effects on direct social environment (e.g. neglect of family, violence) 
While there is no specific information on the possible effects of AB-CHMINACA on the direct social 
environment, the behavioural effects of synthetic cannabinoids include reports of aggressive and 
violent behaviour. This may place users and others at risk of injury. 
Possible effects on society as a whole (public order and safety, acquisitive crime) 
While there is no specific information on the possible effects of AB-CHMINACA on society as a whole, 
as noted, the behavioural effects of synthetic cannabinoids include reports of aggressive and violent 
behaviour. In particular, concern was expressed in this regard to use in certain environments such as 
prisons and psychiatric institutions. In addition, the detection of AB-CHMINACA in cases of suspected 
driving under the influence of drugs indicates a potential for a wider risk to public safety. 
In prisons, alongside the adverse health effects, the market in synthetic cannabinoids has been linked 
to an increase in aggression, violence, bullying, and debt. In some cases this has caused a serious 
threat to the overall safety and security of the prison environment. 
Due to the lack of data, it is not possible at this time to estimate the social risk associated with the 
trafficking and distribution of AB-CHMINACA.  
Economic costs  
Due to the lack of data, it is not possible at this time to estimate whether AB-CHMINACA is 
associated with greater healthcare costs than other drugs. 
Possible appeal to specific population groups 
While no specific examples are available on the possible appeal of AB-CHMINACA to specific user 
groups, it is reasonable to assume AB-CHMINACA may be sought after by those looking for ‘legal’ 
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substitutes for cannabis. This includes individuals subject to drug testing (such as drivers, prisoners, 
those in drug treatment, and those subject to workplace drug testing), as commonly used drug tests 
may be unable to detect the compounds. 
In addition, reports suggest that in some areas, high risk drug users and other vulnerable groups, 
such as the homeless and prisoners, may specifically seek out synthetic cannabinoids because they 
have a reputation for causing profound intoxication, they can be cheap, and are easy to smuggle. 
Information on manufacturing, trafficking, distribution, and the level of 
involvement of organised crime  
There is no specific information to suggest the involvement of organised crime or established criminal 
groups in the manufacture, distribution, and supply of AB-CHMINACA.  
No information has been received by Europol indicating synthesis of AB-CHMINACA within the 
European Union. Information reported to the EMCDDA and Europol indicates that chemical 
companies based in China may be one source of AB-CHMINACA, as well as of other synthetic 
cannabinoids. Seizures, particularly of bulk powders of synthetic cannabinoids are frequently reported 
to have occurred at international European airports and to have been shipped by such companies.  
For AB-CHMINACA, single seizures of powders in excess of 1 kg were reported by Luxembourg, 
France and Spain. When known, the country of origin indicated was China. In a seizure made at 
Roissy Airport in France, the origin of the seizure was reported as China and the final destination was 
Austria. In a seizure made at Madrid-Barajas Airport in Spain, the origin was also reported as China 
and the final destination was France. 
Powders of synthetic cannabinoids, including AB-CHMINACA, are imported into the European Union 
where they are typically processed and packaged into commercial smoking mixtures or sold as 
powder. There are indications of a significant trade in synthetic cannabinoid products within Europe, 
with customs and police in many countries making regular seizures of such products, including herbal 
smoking products containing AB-CHMINACA. 
The largest single seizure of AB-CHMINACA in herbal material was reported by Spain, as part of a 
law enforcement operation. This large-scale operation was carried out in Alicante in March 2016. A 
total of 145,157 packages each containing between 1 and 3 grams of herbal material (that also 
contained the synthetic cannabinoids AMB-FUB and AB-FUBINACA) and 2 bags (of 2 kg each, that 
also contained AMB-FUB) were seized.  
AB-CHMINACA has been available on the European drug market since at least February 2014. A 
total of 24 Member States (Austria, Belgium, Bulgaria, Croatia, Denmark, Estonia, Finland, France, 
Germany, Greece, Hungary, Italy, Latvia, Lithuania, Luxembourg, the Netherlands, Poland, Portugal, 
Romania, Slovakia, Slovenia, Spain, Sweden, and the United Kingdom), Turkey, and Norway, have 
reported detections of AB-CHMINACA. Information reported to the EMCDDA and Europol indicates 
that AB-CHMINACA has been typically seized as herbal material (approximately 190 kg; 150 kg of 
which reported by Turkey) and powder form (approximately 44 kg).  
The available data suggests that herbal smoking mixtures containing AB-CHMINACA are being sold 
directly on the illicit market. The United Kingdom and Lithuania reported seizures of AB-CHMINACA 
which occurred in prisons or other custodial settings. 
RISK ASSESSMENT I AB-CHMINACA  
 
19 
 
Information on any assessment in the United Nations system 
The World Health Organization (WHO) is the specialised United Nations agency designated for the 
evaluation of the medical, scientific, and public health aspects of psychoactive substances under the 
Single Convention on Narcotic Drugs, 1961, and the Convention on Psychotropic Substances, 1971. 
In May 2017, the WHO informed the EMCDDA that AB-CHMINACA will be reviewed at the 39th 
meeting of the WHO Expert Committee on Drug Dependence (ECDD) that will be held in November 
2017. 
Description of the control measures that are applicable in the Member 
States 
Eighteen Member States (Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, 
France, Germany, Hungary, Italy, Latvia, Lithuania, Luxembourg, Slovakia, Slovenia, Sweden, and 
the United Kingdom) and Turkey reported that AB-CHMINACA is controlled under drug control 
legislation. 
 In Bulgaria, AB-CHMINACA was controlled in 2016 according to the ‘Regulation on the 
classification of plants and substances as narcotics’. 
 In Croatia, AB-CHMINACA is controlled within the ‘List of drugs, psychotropic substances, 
plants used to produce drugs and substances that can be used in the production of drugs’, 
Official Gazette no. 10/16. 
 In Cyprus, AB-CHMINACA is controlled by a generic legislation, implemented since 2012 in 
the ‘Existing Law on Narcotic Drugs and Psychotropic Substances’. 
 In the Czech Republic, AB-CHMINACA is controlled since March 2017. 
 In Denmark, AB-CHMINACA is controlled as of 15 June 2017 by an amendment of the 
Executive Order on Controlled Substances. 
 In Estonia, AB-CHMINACA is controlled as of 15 December 2014. 
 In Finland, AB-CHMINACA is controlled as a narcotic drug since 28 September 2015.  
 In France, AB-CHMINACA is controlled since 31 March 2017. 
 In Germany, AB-CHMINACA is included since 22 May 2015 in schedule II ‘narcotics eligible 
for trade but not for medical prescription’. 
 In Hungary, AB-CHMINACA is included, as of 1 January 2015, in Schedule A of Act XXV on 
Medicinal Products of 1998 and on Schedule B of Government Decree 66/2012.  
 In Italy, AB-CHMINACA is included in Table 1 of the Ministerial Decree 309/90 of 1 August 
2016. 
 In Latvia, AB-CHMINACA is included in the Cabinet Regulation N 847 ‘Regulations regarding 
Narcotic Substances, Psychotropic Substances and Precursors to be Controlled in Latvia’ and 
the law ‘On the Procedures for the Coming into force and Application of the Criminal Law’.  
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 In Lithuania, AB-CHMINACA is subjected to control measures by The Republic of Lithuania 
Minister of Health Order No V-267 (21/02/2014) ‘On the amendment of the Ministry of Health 
of the Republic of Lithuania Order No. 5 of 6 January 2000’. 
 In Luxembourg, AB-CHMINACA is controlled by way of generic definition by the Grand-ducal 
decree of 20/04/2009. 
 In Slovakia, AB-CHMINACA is included in Regulation no.121/2015 Coll. as of 1 October 
2015. 
 In Slovenia, AB-CHMINACA is included the ‘Decree on the Scheduling of Illicit Drugs’ that 
was published in Official Gazette No. 22/2016, on 25 March 2016. 
 In Sweden, AB-CHMINACA is regulated under the Act on the Prohibition of Certain Goods 
Dangerous to Health, as of 27 May 2014. 
 In the United Kingdom, AB-CHMINACA is controlled by way of generic definition under the 
1971 Misuse of Drugs Act. 
 In Turkey, AB-CHMINACA was included in Law No.2313 on the Control of Drugs, which was 
published in the Official Gazette on 2 October 2014.  
Three Member States (Austria, Belgium, and Poland) reported that AB-CHMINACA is controlled 
under specific new psychoactive substances control legislation.  
 In Austria, AB-CHMINACA is covered by the Austrian Act on New Psychoactive substances.  
 In Belgium, AB-CHMINACA is controlled by way of generic definition.  
 In Poland, AB-CHMINACA is included in the regulation of the Minister of Health on the list of 
new psychoactive substances. Article 44b of the Act of counteracting drug addiction bans 
manufacturing or introducing new psychoactive substances to trade.  
Norway reported that AB-CHMINACA is controlled under medicinal products legislation. 
Seven Member States (Greece, Ireland, Malta, the Netherlands, Portugal, Romania, and Spain) 
reported that AB-CHMINACA is not subject to control measures at the national level. 
Options for control and the possible consequences of the control 
measures 
Under Article 9.1 of the Council Decision, the option for control that is available at European Union 
level is for the Member States to submit the new psychoactive substance AB-CHMINACA to control 
measures and criminal penalties, as provided for under their legislation, by virtue of their obligations 
under the Convention on Psychotropic Substances, 1971.  
AB-CHMINACA was controlled in China in January 2015. This control measure may at least deter the 
open manufacture and sale of this substance by chemical companies in this country, which are linked 
to the supply of the substance in Europe. 
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There are no studies on the possible consequences of such control measures on AB-CHMINACA. If 
this option of control is pursued, the Committee considers that the following consequences are 
possible. Some of these may apply to any new psychoactive substance. 
 This control option could be expected to limit the availability of AB-CHMINACA and hence the 
further expansion of the current open trade in this substance. 
 A health consequence that might result from this control option is the benefit brought about by 
the presumed reduction in availability and use.  
 This control option could facilitate the detection, seizure and monitoring of AB-CHMINACA 
related to its unlawful manufacture, trafficking and use. In so doing, it could facilitate 
cooperation between the judicial authorities and law enforcement agencies across the 
European Union. 
 This control option would imply additional costs for the criminal justice system, including 
forensic services, law enforcement, and the courts. 
 This control option could lead to replacement with other (established or new) psychoactive 
substances, which may in themselves have public health consequences and social risks.  
 This control option could create an illicit market in AB-CHMINACA with the increased risk of 
associated criminal activity, including the involvement of organised crime. 
 This control option could impact on both the quality/purity and price of any AB-CHMINACA 
still available on the illicit market. The extent to which this will impact on public health, 
criminality, or levels of use, is difficult to predict. 
 It is difficult to predict the impact of this control option on current or future research by the 
pharmaceutical or chemical industries. 
 In order to examine the consequences of control, the Committee wishes to note that it will be 
important to monitor for the presence of AB-CHMINACA on the market post-control, should 
this control option be pursued. 
 Aside from the option for control under those stipulated in Article 9.1 of the Council Decision, 
other options for control may be available to Member States. These may include restricting 
the importation and supply of the substance as some Member States have already done.  
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Conclusion 
N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-
CHMINACA) is an indazole-based synthetic cannabinoid receptor agonist. Information on the 
pharmacology of AB-CHMINACA suggests that it is a potent and full agonist at the CB1 receptor. It 
shows similar effects to THC, but with additional life-threatening toxicity. The high potency of AB-
CHMINACA and the large and variable content of the substance in smoking mixtures constitute a high 
risk of poisoning. 
AB-CHMINACA is often sold as a ‘legal’ replacement for cannabis. It is typically administered by 
smoking a herbal mixture that is either from a ready-to-use commercial ‘legal high’ product, or, less 
commonly, that is self-prepared. Similar to herbal cannabis, the mixture is usually prepared for 
smoking as a hand-rolled cigarette (‘joint’) but it may also be smoked in a pipe or ‘bong’. AB-
CHMINACA can also be inhaled using an e-cigarette or other vaporisation device. 
AB-CHMINACA has been available on the drug market in the European Union since at least February 
2014 and has been detected in 24 Member States, Turkey, and Norway. It is sold online as 
commercially branded ‘legal high’ products and powders. It may also be sold directly on the illicit drug 
market. 
The available data suggests that AB-CHMINACA is used by cannabis users, by those who are 
regularly subjected to drug testing procedures (including those in prison), and by ‘psychonauts’. It 
may also be used by high risk drug users and other marginalised groups (such as prisoners), as 
synthetic cannabinoids have gained a reputation for causing profound intoxication, they can be cheap, 
and are easy to smuggle. However, no further information on the size and demand and the 
characteristics of these groups of people is available.  
Seven acute intoxications with confirmed exposure to AB-CHMINACA have been reported by 4 
Member States. Where known, the features of the poisoning were similar to those found with other 
synthetic cannabinoids. 
Thirty-one deaths with confirmed exposure to AB-CHMINACA have been reported by 6 Member 
States. In at least 9 of these cases, AB-CHMINACA was either the cause of death or is likely to have 
contributed to the death. 
Due to the nature of AB-CHMINACA, both non-fatal intoxications and deaths are likely to be under-
detected and under-reported. 
There is currently no approved antidote to poisoning caused by synthetic cannabinoids such as AB-
CHMINACA. 
Reports suggest a possibility for violence and aggression following use of synthetic cannabinoids. In 
particular, concern was expressed in this regard to use in certain environments, such as prisons and 
psychiatric institutions. In addition, the detection of AB-CHMINACA in cases of suspected driving 
under the influence of drugs indicates a potential for a wider risk to public safety. 
There is no specific information on the involvement of organised crime in the manufacture, distribution 
(trafficking), and supply within the European Union. There is limited information on the chemical 
precursors and the synthetic routes used to manufacture the AB-CHMINACA detected within the 
European Union. The largest single seizure of AB-CHMINACA was in Luxembourg in 2015, when 4.8 
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kg of powder that was in transit was seized by customs. During 2017, AB-CHMINACA continued to be 
seized by law enforcement within the European Union. 
AB-CHMINACA has no recognized human or veterinary medical use in the European Union, nor, it 
appears, elsewhere. There are no indications that AB-CHMINACA may be used for any other purpose 
aside from as an analytical reference standard and in scientific research. 
AB-CHMINACA is not listed for control in the Single Convention on Narcotic Drugs, 1961, nor in the 
Convention on Psychotropic Substances, 1971. AB-CHMINACA is currently under assessment by the 
United Nations system.  
Eighteen Member States and Turkey control AB-CHMINACA under drug control legislation. Three 
Member States and Norway control AB-CHMINACA under other legislation. 
As for any new psychoactive substance, many of the questions related to AB-CHMINACA that are 
posed by the lack of data on the risks to individual health, risks to public health, and social risks, could 
be answered through further research. Areas where additional information would be important include 
studies on: rationale for use, prevalence and patterns of use (including targeted studies that examine 
user groups and risk behaviours); the market; chemical profiling; complete pharmacological profiling; 
metabolic pathways; behavioural effects; acute and chronic toxicity; the potential interaction between 
AB-CHMINACA and other substances; dependence and abuse potential; and the public health risks 
associated with its use. 
The Committee notes that a decision to control AB-CHMINACA has the potential to bring with it both 
intended and unintended consequences. Potential intended consequences include reduced levels of 
availability and ultimately use. This may reduce the health and social risks arising from the use of AB-
CHMINACA. It is important to recognise that a potential unintended consequence of control may be 
the manufacture and availability of other substances. Indeed, pharmacologically analogous 
substances that may replace AB-CHMINACA are already being sold on the drug market. The 
implementation of control measures may also lead to the criminalisation of those who continue to use 
this substance with the possible attendant risks of socio-economic stigmatisation and marginalisation. 
Should control measures be adopted, they should be accompanied by the gathering and 
dissemination of accurate information on AB-CHMINACA to users, practitioners, policy makers, and 
decision makers.
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ANNEX 1 
Introduction 
Synthetic cannabinoid receptor agonists (synthetic cannabinoids), such as AB-CHMINACA, are a 
group of substances that mimic the effects of tetrahydrocannabinol (THC), which is a substance found 
in cannabis (1). THC is responsible for many of the psychoactive effects of cannabis which give that 
feeling of being 'stoned' (or 'high') (Gaoni et al, 1964; Huestis et al., 2001; Pertwee, 2014). THC 
causes these effects by activating a receptor in the brain called the cannabinoid receptor type 1 (CB1 
receptor) (Huestis et al., 2001; Pertwee, 2005a). This receptor is part of a signalling system in the 
body called the endocannabinoid system, which helps regulate, among other things, behaviour, 
mood, pain, appetite, sleep, and the immune system (Pertwee, 2015) (2). Because synthetic 
cannabinoids activate the CB1 receptor in a similar way to THC, some of their effects appear to be 
similar to cannabis. Most prominently, they are able to create a feeling of being ‘stoned’.  
Synthetic cannabinoids were originally developed by scientists to study the endocannabinoid system, 
as well as provide insights into disease, and to help make new medicines (Pertwee, 2005a; Pertwee, 
2005b; Pertwee, 2015; Reggio, 2009). From around 2006, they began to appear in Europe in 
products called ‘Spice’ that were sold as ‘legal’ replacements to cannabis (Auwärter et al., 2009; 
EMCDDA, 2009; Jack, 2009). In these products, synthetic cannabinoids had been mixed with plant 
(herbal) material which could then be smoked as cigarettes (‘joints’) (Auwärter et al., 2009; EMCDDA, 
2009; EMCDDA, 2017a; Jack, 2009). Such products have been referred to by a variety of names, 
including ‘herbal smoking mixtures’, ‘herbal incense’, ‘Spice’, ‘K2’, and ‘synthetic cannabis’. Since 
2008, almost 180 synthetic cannabinoids have been identified on the drug market in hundreds of 
different products. They are the largest group of substances that are monitored by the EMCDDA 
through the European Union Early Warning System on New Psychoactive Substances (EU Early 
Warning System) (EMCDDA, 2017b). 
In accordance with Article 5 of the Council Decision 2005/387/JHA on the information exchange, risk-
assessment and control of new psychoactive substances (3), on 25 April 2017, the EMCDDA and 
Europol launched the Joint Report procedure for N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-
(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA) on the basis of data reported by the 
Member States to the EU Early Warning System in accordance with Article 4 of the Council Decision. 
The information collection process for the Joint Report was completed in June 2017. The report was 
submitted to the Institutions of the European Union in July 2017 (EMCDDA, 2017c). In accordance 
                                                          
(1) (–)-trans-Δ9-tetrahydrocannabinol. 
(2) The endocannabinoid system helps regulate a large number functions in the body. It consists of the cannabinoid CB1 and 
CB2 receptors, the endocannabinoids (such as anandamide) which act as endogenous agonists for these receptors, and the 
processes responsible for endocannabinoid biosynthesis, cellular uptake, and metabolism. Important exogenous agonists for 
the cannabinoid receptors are (–)-trans-Δ9-tetrahydrocannabinol (THC) which is the major active substance in cannabis, and 
the synthetic cannabinoids found in legal high-type smoking mixtures. Data from laboratory studies suggests that the 
endocannabinoid system plays an important protective role. For example, in response to some diseases the body increases the 
amount of endocannabinoids it produces which can reduce unwanted symptoms or slow disease progression (Pertwee, 2005a; 
Pertwee, 2005b; Pertwee, 2015). 
(3) OJ L 127, 20.5.2005, p. 32.  
Technical report on N-(1-amino-3-methyl-1-
oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-
carboxamide (AB-CHMINACA) 
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with Article 6 of the Council Decision, on 14 September 2017, the Council of the European Union 
requested that a risk assessment on AB-CHMINACA should be carried out by the extended Scientific 
Committee of the EMCDDA. 
In order to prepare for a risk assessment that has been convened under the Council Decision and to 
facilitate the risk assessment process, the EMCDDA is responsible for the collection and analysis of 
data on the substance to be assessed as well as drafting a technical report. This technical report has 
been prepared for the risk assessment AB-CHMINACA that will be held at the EMCDDA premises in 
Lisbon on 7 November 2017. 
Some of the sections in this report were prepared under EMCDDA contracts (ref. CT.16.SAT.0101.1.0 
and CT.17.SAT.0110.1.0). 
Data sources 
The information in this technical report is derived from: 
 data reported by the Member States, Turkey and Norway to the EMCDDA and Europol in 
accordance with the Council Decision (EMCDDA, 2017c); and,  
 data collected through systematic searches of open source information, including the 
scientific and medical literature, patents, official reports, grey literature, Internet drug 
discussion forums and related websites, and online vendors selling AB-CHMINACA. 
Search strategy  
Literature searches used both chemical structure and text queries in online databases; searches were 
conducted in August 2017. The retrieved publications were then reviewed for additional relevant 
references (snowballing technique). 
Textual searches were conducted online in PubMed (National Center for Biotechnology Information), 
Web of Science™ (Thomson Reuters), and in popular English-language drug forums. The search 
term used was: ‘AB-CHMINACA’. Medline and Google Scholar were searched for ‘AB-CHMINACA’ 
(with and without hyphen) and the IUPAC names of this compound stated in this document. In 
addition, exact chemical structure-based searches were done in SciFinder (American Chemical 
Society, Chemical Abstract Service) and Reaxys (Elsevier). Google and specific drug user discussion 
forums and related websites (such as Bluelight, Eve and Rave, and Erowid) were searched for the 
terms: ‘AB-CHMINACA’ alone or in combination with ‘buy’, ‘shop’, ‘research chemical’, ‘synthetic 
cannabinoid’, ‘dosing’, ‘intoxication’, ‘kaufen’, ‘räuchermischung’, ‘powder’, ‘synthesis’. Additionally, 
colleagues within the scientific network of the authors were contacted to obtain information. 
The REACH registered substances database hosted by the European Chemicals Agency (ECHA) 
was searched using the CAS registry numbers listed below. The searches returned no hits. 
Note 
It is important to note that when interpreting the information on self-reported user experiences in this 
report, it is not possible to confirm the specific substance(s) that have been claimed to be used; 
similarly it is also not possible to confirm the strength, purity, dose/amount, etc., used. Moreover, the 
actual composition of the substance/product claimed to be used may differ over time and different 
geographical areas. In addition, the information provided on user websites may not necessarily be 
representative of other users of AB-CHMINACA and should be regarded as illustrative only. In 
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general, given the difficulties of collecting accurate self-reported data, it should be interpreted with 
caution. 
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Section A. Physical, chemical, pharmaceutical and pharmacological 
information 
A1. Physical, chemical, and pharmaceutical information 
A1.1. Physical and chemical description 
Chemical description and names 
N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide, also known 
as AB-CHMINACA (Figure 1) is a synthetic cannabinoid receptor agonist (synthetic cannabinoid). The 
common name for the substance is derived after its structural features (7): a methyl amino butanone 
linked group (AB), a cyclohexylmethyl tail (CHM), an indazole core (INA) and a carboxamide linker 
(CA).  
AB-CHMINACA contains a stereogenic centre and therefore two possible enantiomers may exist, (R)- 
and (S)-AB-CHMINACA.(S)-AB-CHMINACA was originally described in a patent application by Pfizer 
Inc. and published in 2009 (compound 21) (Buchler et al., 2009). It is worth noting that the 
compounds described in the patent literature only show the (S)-configuration (Buchler et al., 2009). 
Based on the literature and the most likely precursors to be used, an (S)-configuration of the 
stereocentre could be expected. However, there is no representative information on the enantiomeric 
composition of the samples of AB-CHMINACA detected within the European Union. 
AB-CHMINACA was first reported to the EMCDDA in 2014 (Section C). 
AB-CHMINACA contains an indazole core, which is a common structural feature in many of the 
synthetic cannabinoids monitored by the EMCDDA, such as ADB-CHMINACA (Figure 1). Five 
synthetic cannabinoids have been recently controlled under Schedule II of the United Nations 
Convention on Psychotropic Substances, 1971: JWH-018 (8), AM-2201 (9), MDMB-CHMICA (10), 5F-
APINACA (5F-AKB-48) (11) and XLR-11 (12). Other synthetic cannabinoids, including ADB-
CHMINACA (13) (EMCDDA, 2017d), 5F-MDMB-PINACA (5F-ADB) (14) (EMCDDA, 2017e), and 
CUMYL-4CN-BINACA (15) (EMCDDA, 2017f) (Figure 1), have also been the subjects of Joint Reports 
by the EMCDDA and Europol. 
 
 
 
 
 
 
 
 
                                                          
(7) The common name for the substance is derived after its structural features. Different naming systems exist and are used for 
applying short/code names to synthetic cannabinoids. 
(8) JWH-018: (Naphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone. 
(9) AM-2201: [1-(5-Fluoropentyl)-1H-indole-3-yl](naphthalen-1-yl)methanone. 
(10) MDMB-CHMICA: Methyl (2S)-2-{[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]amino}-3,3-dimethylbutanoate. 
(11) 5F-APINACA: N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide. 
(12) XLR-11: [1-(5-Fluoropentyl)-1H-indole-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone. 
(13) ADB-CHMINACA: N-[1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide. 
(14) 5F-MDMB-PINACA (5F-ADB): Methyl (2S)-2-{[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino}-3,3-dimethylbutanoate. 
(15) CUMYL-4CN-BINACA: 1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide. 
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FIGURE 1  
The molecular structure, molecular formula and molecular mass of AB-CHMINACA (left) and 
ADB-CHMINACA (right). 
  
  
C20H28N4O2 C21H30N4O2 
356.47 g/mol 370.50 g/mol 
 
Names and other identifiers 
Systematic International Union of Pure and Applied Chemistry (IUPAC) names:  
N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide 
(racemate) 
Chemical Abstract name:  
N-[1-(Aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide 
(racemate); 
N-[(2S)-1-Amino-3-methyl-1-oxobutan-2-yl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide 
((S)-enantiomer);  
N-[(1S)-1-(Aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide 
((S)-enantiomer) 
Other names:  
N-[(2S)-1-Amino-3-methyl-1-oxo-2-butanyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide 
((S)-enantiomer) 
Chemical Abstract Service Registry Numbers (CAS RNs) (16): 
1805788-79-7: racemate  
1185887-21-1: ((S)-enantiomer) 
  
                                                          
(16) The Chemical Abstract Service Registry Number (CAS RN) is a unique numeric identifier assigned by the Chemical 
Abstract Service Division of the American Chemical Society to a specific, single chemical substance. 
N
N
O
NH NH2
O
N
N
O
NH NH2
O
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PubChem SID:  
70969900 (racemate) (17) 
IUPAC International Chemical Identifier Key (InCHI Key)(18):  
KJNZIEGLNLCWTQ-UHFFFAOYSA-N (racemate) 
KJNZIEGLNLCWTQ-QGZVFWFLSA-N ((R)-enantiomer) 
KJNZIEGLNLCWTQ-KRWDZBQOSA-N ((S)-enantiomer); 
SMILES (19): 
CC(C)C(C(=O)N)NC(=O)c1c2ccccc2n(n1)CC3CCCCC3 (racemate) 
[H][C@@](C(C)C)(C(=O)N)NC(=O)c1c2ccccc2n(n1)CC3CCCCC3 ((R)-enantiomer) 
CC(C)[C@H](NC(=O)c1nn(CC2CCCCC2)c3ccccc13)C(N)=O ((S)-enantiomer) 
Common names:  
AB-CHMINACA 
Street names:  
‘Spice’, ‘K2’, ‘legal weed’, ‘synthetic cannabis’, ‘herbal incense’ 
AB-CHMINACA has been detected in herbal smoking mixtures bought from vendors on the surface 
web as part of the EU project ‘SPICE Profiling’ project (JUST/2013/ISEC/DRUGS/AG/6421) 
(Moosmann et al., 2017).  
These products bore invented names such as: 2012, After Party, AK 47, 24 Karat Gold, AK-47 Gelb, 
Aliens, Armageddon, Astro, Aura Core, Aura Sniper, Bad Monkey, Barely legal, Be Happy, Beach 
Party, Big Party, Bionic Sphere, Black Diamonds, Blaze, Bonzai, Bonzai 2.0, Bonzai Banana, Bonzai 
Cherry, Bonzai Citrus, Bonzai DNS, Bonzai Summerboost, Bonzai Winterboost neu, Bonzai 
Winterboost, Brazil Gold, British Blend, Buzzooka, Caramba, Cherry-Apple, Citrus Bomb, Citrus 
Monster, Couchtrip, Couchtrip Strawberry, Dark Night, Denim, Desert, Dimension 8, Dragon Fire, E-
Liquid Apfel, E-Liquid Vanille, Explosion, Flight Risk, G20, Galaxy, Galaxy "2", Gangsta, Geeked up, 
Gorby Mix, Green Giant, Green Leaves, Hafnium, Hammer Head, Hard Play, Hausmarke, Head 
Crash, Head Trip "Premium-Produkt", Herbal Tank, Hexen Meister, High School, Holy Shit, Jamaican 
Gold Extreme, Jamaican Gold Extrime, Joker, Kidz, Magic, Mandala, Maui, Moonlight, Namifu, New 
Bonzai Citrus, New Yama, Nexus Blue, Nexus Extreme, Nexus Extreme Blueberry, Nexus Extreme 
Chocolate, Nexus Extreme Strawberry, Nexus Extreme Vanilla, Nexus Red, Night Angels, Panic, Play 
Hard, Pure Sin, Red Russian, Shiva Passion, SHOOP, Spice 2.0, Springbang, Supernova, SWEED 
classic, SWEED Gold, SWEED Platin, Toxic Snake "Legal Hash", Vulkan, WTF.  
                                                          
(17) https://pubchem.ncbi.nlm.nih.gov/compound/70969900 
(18) InChI Key is a unique, non-proprietary structural identifier of chemical substances useful in electronic sources. 
(19) The simplified molecular-input line-entry system (SMILES) is a unique, non-proprietary structural identifier of chemical 
substances useful in electronic sources.  
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Other street names reported to the EMCDDA are: Aromatic Pot Pourri, Jamaican Gold Supreme, 
Jamaican Gold Extreme, Yama, Bonzai Summer Boost, Bonzai Winter Boost, Bonzai Citrus, Blaze, 
Bubblegum, Manga Xtreme, Manga XXL, V.I.P., Love, R&B, King Size Slim Rolling Papers, Vertex 
Ultra Extreme Incense Pirate Edition, Mary Jean, Waldemar Uszkiewicz Taak, Vertex Pirate Edition 
Ultra Extreme Incense, Galaxy Herbal Incense: Althea officinalis, Matt Hardener, Aura mystic Bulc. 
Manufacturers of herbal smoking mixtures frequently change the synthetic cannabinoids in the 
products, which means that product names are not a reliable source of information regarding the 
actual substances that are present (e.g. Frinculescu et al., 2017, Moosmann et al., 2015). 
Identification and analytical profile 
Physical description  
In its pure form AB-CHMINACA is a white to off-white crystalline powder (Lipomed, 2017). It is soluble 
in ethanol, DMSO and DMF (dimethyl formamide) to approximately 3, 10 and 5 mg/mL, respectively. 
The substance is sparingly soluble in aqueous buffers (Cayman Chemical Company, 2017). 
The melting point is 85 ± 5 °C (Lipomed, 2017). The boiling point is not available in the literature. 
However, the boiling point can be estimated to be below 350 °C according to the retention time of AB-
CHMINACA in GC-MS analysis (Moosmann et al., 2017). 
AB-CHMINACA carries one asymmetric carbon atom. Based on the patent literature and the most 
likely precursors, an (S)-configuration of the stereocentre can be assumed, possibly because one of 
the reagents used in its preparation (L-valinamide, see below) is derived from inexpensive natural 
sources or produced by industrial fermentation. The biological evaluation of the compounds described 
in the Pfizer patents exclusively report on compounds with the (S)-configuration and since data on the 
(R)-form were not included, it is not known how the stereochemistry affects activity on cannabinoid 
receptors. The absolute configuration of the structurally similar synthetic cannabinoid MDMB-CHMICA 
has recently been described in the literature which confirmed the (S)-configuration in samples from 
the drug market (including a seizure of a powder as well as ‘legal high’ type herbal smoking mixtures) 
(Andernach et al., 2016). 
AB-CHMINACA shares structural features with other synthetic cannabinoids such as AB-PINACA and 
MA-CHMINACA or AMB-CHMINACA which have been described in the patent literature and/or are 
offered on the drug market (Figure 2) (Buchler et al., 2009). 
FIGURE 2  
Chemical structures of AB-PINACA and MA-CHMINACA (AMB-CHMINACA) 
 
 
N
N
O
NH NH2
O
N
N
O
NH O
O
RISK ASSESSMENT I AB-CHMINACA  
 
31 
 
AB-PINACA MA-CHMINACA (AMB-CHMINACA) 
 
Chemical stability and typical reactions 
The terminal and the secondary amide bonds of AB-CHMINACA may be cleaved chemically or 
enzymatically. 
Hydrolysis of the amide functions can be expected to occur during smoking as it was observed by 
analysis of smoke condensates (Franz et al., 2016). Most of the known free carboxylic acids formed 
by hydrolysis of similar compounds are not active at the CB1 receptor (Buchler et al., 2009 and 2011). 
Therefore, the hydrolysis product of AB-CHMINACA might also not be active. 
Hess et al., investigated the freeze/thaw stability as well as long term stability of synthetic 
cannabinoids in human serum samples (Hess et al., 2016a). They showed that AB-CHMINACA 
degraded less than 10% in serum during three freeze/thaw cycles (at least 20 h freezing and one hour 
thawing at room temperature). The long term stability of AB-CHMINACA in serum was given for at 
least 105 days at -20 °C, 105 days at 4 °C and over 315 days at room temperature (stability criterion: 
measured degradation below 20%). 
Analytical profile 
The analytical profile of AB-CHMINACA has been described in a publication utilizing EI-MS, ESI-EPI-
MS/MS, IR and UV-VIS detection (Langer et al., 2016). 
The UV maxima of AB-CHMINACA were reported at 303 nm in methanol.  
IR data are as follows: wavenumber (cm-1): 3331 (w), 3193 (w), 2926 (m), 2852 (w), 1649 (s), 1527 
(s), 1491 (m), 1368 (w), 1303 (w), 1175 (m), 749 (s), 603 (m), 568 (m). Additionally, an FTIR spectrum 
has been published by Veress and Nagy (2015). 
NMR data have been reported by Buchler et al., (2009) and Uchiyama et al., (2014). 
The mass spectrometric fragmentation patterns of AB-CHMINACA was reported in publications of 
Akamatsu et al., (2016), Uchiyama et al., (2014) and Langer et al., (2016). Additionally, a GC-PI-MS 
spectrum was published by Akutsu et al., (2017), a paperspray HRMS method by Kennedy et al., 
(2016) and GC-EI-MS, positive and negative GC-CI-MS spectra were published by Umebachi et al., 
(2017). Analytical data for AB-CHMINACA have also been published (Slovenian National Forensic 
Laboratory, 2015; LaGory et al., 2014). 
A voltammetric determination method of indole and indazole synthetic cannabinds, including AB-
CHMINACA, has also been described (Dronova et al., 2016). 
Quantification of AB-CHMINACA in herbal smoking mixtures can be carried out according to the 
general procedure described by the UNODC, e.g. by HPLC-DAD analysis (UNODC, 2013). 
Additionally, quantification of AB-CHMINACA in herbal material has been carried out using NMR 
analysis by Dunne et al., (2017) and by DART-MS by Nie et al., (2016). 
For blood serum analysis, the parent compound is the main analytical target. Quantification of 137 
authentic serum samples positive for AB-CHMINACA showed that concentrations detected are often 
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in the sub-ng/mL range (mean: 7.7 ng/mL, median: 2.6 ng/mL, range 0.1 – 81 ng/mL) (Moosmann et 
al., 2017). Taking into account an anticipated serum/blood ratio slightly below 1 (Schaefer et al., 
2015), this concentration range is in accordance with the data Peterson et al., obtained from 
analysing whole blood samples (1 to >10 ng/g) (Peterson and Couper, 2015). LC-MS/MS 
instrumentation can be regarded as the gold standard for analysis of serum/blood samples due to its 
high sensitivity which is particularly useful when applied in abstinence control settings. A fully 
validated method for the detection of AB-CHMINACA in serum samples has been published using LC-
MS/MS (detected in 9 samples: < 0.66 – 21.3 ng/mL) by Hess et al., (2017). In addition, two LC-
MS/MS methods for the detection of AB-CHMINACA in whole blood were published, also applying 
LC-MS/MS (Peterson and Couper, 2015; Tynon et al., 2017). A semiquantitative approach was 
employed to estimate the concentration of AB-CHMINACA in serum samples collected from three 
acute intoxication cases involving this compound (1.8 ng/mL, 0.28 ng/mL and 0.05 ng/mL) 
(Abouchedid et al., 2017). 
For urine analysis, the identification of the main in vivo metabolites is recommended prior to setting up 
an analytical method as AB-CHMINACA is not excreted unchanged in urine to a relevant extent, 
which can make its detection in this matrix challenging. However, the detection of the parent molecule 
in a human urine sample collected from a fatal intoxication has been reported with a concentration of 
239 pg/mL (Minakata et al., 2017). 
Based on the analysis and evaluation of authentic urine samples, metabolites formed by mono-
hydroxylation (at the cyclohexyl moiety) and hydrolysis of the terminal amide function seem to be the 
most suitable targets for a reliable detection of exposure to AB-CHMINACA (20). Two articles on the 
identification of AB-CHMINACA metabolites in authentic human urine samples have been published 
(Erratico et al., 2015; Wurita et al., 2016), confirming these findings. AB-CHMINACA and its ‘carboxy’ 
metabolite (presumably the terminal amide hydrolysis product) have been detected in urine samples 
obtained from users (Brajković et al., 2015). 
For all metabolites having undergone hydrolysis of the terminal amide function it has to be noted that 
they may also be formed after exposure to the synthetic cannabinoid MA-CHMINACA (Figure 2), and, 
consequently, when detected alone do not unequivocally prove exposure to AB-CHMINACA. 
Another aspect which has to be taken into account is the thermolytic formation of two AB-CHMINACA 
metabolites during smoking which could bias the detected metabolic profile (Franz et al., 2016). A 
GC-MS analysis of stomach content collected from an acute intoxication case revealed the presence 
of AB-CHMINACA, AB-FUBINACA, α-PHP, α-PVP, diazepam, and quetiapine (Klavž et al., 2016) 
Methods and chemical precursors used for the manufacture  
Synthesis 
Information about the methods used for the synthesis of the AB-CHMINACA that has been detected 
on the drug market in Europe has not been reported to the EMCDDA. The synthesis of the AB-
CHMINACA (S)-enantiomer was first published in a patent application of Buchler et al., (compound 
21) starting from methyl 1H-indazole-3-carboxylate as shown in Figure 3 (Buchler et al., 2009). It is 
possible that the methods described therein might have been used to manufacture the AB-
CHMINACA that has been detected in Europe. 
 
                                                          
(20) Institute of Forensic Medicine, Forensic Toxicology, Medical Center – University of Freiburg, Germany. 
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FIGURE 3 
Synthesis route for AB-CHMINACA starting from methyl 1H-indazole-3-carboxylate. 
 
Reagents: (a) base (e.g. sodium hydride, potassium tert-butoxide, sodium hexamethyldisilazide, or potassium 
carbonate) and (X-methyl)cyclohexane (X = leaving group; e.g. halogen, mesilate, or tosylate); (b) saponification 
with aqueous base (e.g. sodium hydroxide, potassium hydroxide, or lithium hydroxide); (c) amide bond coupling 
with L-valinamide using a carboxyl group activating reagent (e.g. N,N´-dicyclohexylcarbodiimide (DCC) or 1-[3-
(dimethylamino)propyl]-3-ethylcarbodiimide (EDC), either alone or in combination with 1-hydroxybenzotriazole 
(HOBt)) and a uronium reagent (e.g. O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate 
(HATU), O-(benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU), or O-(benzotriazol-1-yl)-
1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU)). 
The respective (R)-enantiomer might be synthesized under identical conditions using D-valinamide 
instead of L-valinamide in reaction step (c). Using valinamide as a racemate in reaction step (c) would 
lead to racemic AB-CHMINACA. 
It was also described that the starting compound methyl 1H-indazole-3-carboxylate can be prepared 
from 1H-indole-2,3-dione using the procedure of Johnson and Rodgers (2005) as shown in Figure 4. 
FIGURE 4 
Synthesis route for methyl 1H-indazole-3-carboxylate starting from 1H-indole-2,3-dione. 
 
Reagents: (d) NaOH (sodium hydroxide); (e) NaNO2 (Sodium nitrite) and H2SO4 (sulfuric acid); (f) SnCl2 (tin(II) 
chloride) and HCl (hydrochloric acid); (g) subsequent ring closure; (h) MeOH (methanol) and an acid catalyst. 
 
In principle, reaction step (a) can also produce the N2-alkylated 2H-regioisomer (IUPAC: methyl 2-
(cyclohexylmethyl)-2H-indazole-3-carboxylate) as a by-product, depending on the base and alkylating 
agent used. Longworth and co-workers published an evaluation of the reaction conditions regarding 
regioselectivity of the alkylation step, starting the synthesis from 1H-indazole-3-carboxylic acid. 
(Longworth et al., 2016). The use of potassium tert-butoxide in the alkylation step affords mainly the 
N1-cyclohexylmethly derivative, while a substantial amount of the N2 alkylated regioisomer is formed 
if potassium carbonate is used. 
According to the synthesis routes described in Figure 3 and Figure 4 potential precursors of AB-
CHMINACA are 1H-indole-2,3-dione, 1H-indazole-3-carboxylic acid, methyl 1H-indazole-3-
carboxylate, L-valinamide (for synthesis of the (S)-enantiomer), and (bromomethyl)cyclohexane. 
Other 1H-indazole-3-carboxylic acid esters might be suitable as alternative starting material. 
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Although not documented, the N1-alkylation can be carried out on the indazolyl valinamide derivative 
as the last step under conditions as described for serotonin receptor antagonists (Furlotti et al., 2012; 
Schaus et al., 1998) and, recently, a metabolite of the syntethic cannabinoid receptor agonist AKB-48 
(Wallgren et al., 2017). 
Commercially available domestic or industrial products which could be used for synthesis may contain 
potentially toxic substances, including heavy metals and organic solvents. Use of such products as 
reagents may result in serious toxic effects if the resultant impure product is consumed. The herbal 
material which is used as a basis for the smoking mixtures may also contain toxicologically relevant 
substances like e.g. pesticides potentially present in the plant material as well.  
Typical impurities encountered in seized and collected samples 
There are no quantitative data available on the impurities detected in seized and collected samples 
reported to the EMCDDA. However, the 2H-analogue, that is the N2-alkylated regioisomer, of AB-
CHMINACA has been identified in a ‘herbal mixture’ obtained from the Internet in Japan (Uchiyama et 
al., 2015). The N2-regioisomer of AB-CHMINACA was observed to be significantly less active at the 
CB1 and CB2 receptors and might not contribute to the cannabimimetic effects (Longworth et al., 
2016). Nevertheless, the toxicological properties of this by-product have not been evaluated. Further 
variations of the reagents, conditions and synthesis procedures may cause additional, possibly, toxic 
impurities. 
A1.2. Physical/pharmaceutical form  
Data from seizures and collected samples reported to the EMCDDA show that AB-CHMINACA has 
typically been detected in herbal/plant material. Other forms have also been encountered, including 
powders. The Pfizer Inc. patent also included the use of synthetic cannabinoids in a range of 
pharmaceutical compositions depending on the methods used for administration (Buchler et al., 
2009).  
For the production of smoking mixtures, the substance is dissolved in an organic solvent (e.g. 
acetone) and applied to the plant material—such as damiana (Turnera diffusa) or marshmallow 
(Althaea officinalis)—either via spraying or soaking and subsequent evaporation of the solvent 
(EMCDDA, 2017a). 
A1.3. Route of administration and dosage  
AB-CHMINACA is offered by online retailers either as powder (‘research chemical’) or in the form of 
herbal smoking mixtures. The presence of AB-CHMINACA or any other particular synthetic 
cannabinoid is not usually disclosed in these latter products. Some synthetic cannabinoids, including 
AB-CHMINACA, have also been offered in the form of e-liquids for vaping (Kennedy et al., 2016). 
Additionally, consumers might also prepare AB-CHMINACA containing e-liquids at home by 
dissolving the powdered form in propylene glycol. 
The most common route of administration for synthetic cannabinoids is smoking either ready-to-use 
or self-prepared ‘herbal mixtures’ as a joint or utilizing a vaporizer, ‘bong’ or pipe. Oral consumption of 
synthetic cannabinoids has also been described. In the case of oral consumption a strong first-pass-
effect can be expected. Additionally, the bioavailability can possibly be further reduced due to limited 
solubility and absorption or efflux pumps (e.g. multidrug resistance protein 1). 
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Lefever et al., (2017) developed a model of e-cigarette use in mice to compare the differences in 
pharmacological effects after intraperitoneal injection and aerosol inhalation of AB-CHMINACA and 
other synthetic cannabinoids. They demonstrated that AB-CHMINACA showed a full cannabinoid 
profile in three bioassays after both application routes. The time course for hypothermia after AB-
CHMINACA exposure caused a faster onset and shorter duration after inhalation compared to 
injection. Since the time course of hypothermia is linked to the action of the synthetic cannabinoid, the 
authors stated that ‘one particular concern with quick-onset and short-acting synthetic cannabinoids is 
that users will smoke or vape more frequently to maintain their high, thereby also exposing 
themselves to greater potential for toxicities of these compounds’. Similar observations were noted for 
locomotor activity where AB-CHMINACA and CP 55,940 showed similar dose–response curves upon 
aerosol inhalation exposure but AB-CHMINACA was about tenfold less active upon injection; the 
difference in the antinociceptive activity of these two cannabinoids were less marked though CP 
55,940 was more active upon injection. 
Based on a limited number of self-reported experiences posted on Internet discussion forums (21), 
dosages of AB-CHMINACA range from 0.1 to 0.4 mg. When consuming smoking mixtures, users will 
be unaware of the dose they are exposed to. Studies have found that many of these products are 
inhomogeneous with respect to the content of active ingredients (Logan et al., 2012; Zuba and 
Byrska, 2013; Moosman et al., 2015; Kikura-Hanajiri, 2013). Both high intra- as well as inter-package 
variability was observed for many synthetic cannabinoids (Moosman et al., 2015). (Section D.3.4.) 
The content of AB-CHMINACA was analysed by Langer et al., in three products. The products 
contained 63 mg/g, 87 mg/g, and 92 mg/g AB-CHMINACA. None of the products contained other 
active ingredients (Langer et al., 2016). 
In addition, the content of AB-CHMINACA was also analysed in 33 products received within the 
product monitoring performed in the Institute of Forensic Medicine Freiburg, Germany. The 
concentrations ranged from 0.1% (w/w) to 16.4% (w/w), the median was 3.2% (w/w) and the mean 
5.2% (w/w) (Moosmann et al., 2017). In this study no homogenisation was carried out prior to analysis 
in order estimate the doses that users could be exposed to under real world use (Langer et al., 2016). 
Kennedy et al., (2016) detected AB-CHMINACA in one e-cigarette liquid, next to three additional 
synthetic cannabinoids. 
Seizure data as well as studies have shown that it is relatively common for more than one synthetic 
cannabinoid to be added to ‘herbal mixtures’ (Moosman et al., 2015). In Japan, Kikura-Hanajiri et al., 
(2013) detected an average number of 2.6 synthetic cannabinoids per product. The maximum number 
of synthetic cannabinoids detected in one mixture by these authors was ten.  
Continuous market monitoring within the EU ‘SPICE’ projects included the analysis of 975 smoking 
mixtures between August 2014 and June 2017. AB-CHMINACA was detected in 148 samples (15%), 
with 72% containing AB-CHMINACA only, 19% containing AB-CHMINACA and one additional 
synthetic cannabinoid, and 9% containing AB-CHMINACA and two or more (up to 6) additional 
synthetic cannabinoids (Moosmann et al., 2017). Within the Welsh drug checking project WEDINOS, 
AB-CHMINACA was detected in six herbal mixtures and in five powders sent for analysis between 
May 2014 and October 2015 (WEDINOS, 2017). 
 
                                                          
(21) http://drugs.tripsit.me/ab-chminaca. Accessed: 07.10.2017 
RISK ASSESSMENT I AB-CHMINACA  
 
36 
 
A2. Pharmacology, including pharmacodynamics and pharmacokinetics  
Pharmacologically, AB-CHMINACA is a cannabinoid receptor agonist. 
Pharmacodynamics 
AB-CHMINACA is a highly potent full agonist at the CB1 receptor of the endocannabinoid system. In 
the patent application by Pfizer Inc. a Ki value at the human CB1 receptor of 0.519 nM and EC50 of 
2.55 nM (GTPγS assay) is reported (Buchler et al., 2009). Wiley et al., (2015) report a Ki of 0.78 nM 
([3H]CP-55,940) for hCB1 and an EC50 of 7.4 nM (GTPγS assay) (Table 1). Other EC50 values (GTPγS 
assay) reported for AB-CHMINACA for hCB1 were 0.226 nM (CP-55,940 EC50 = 0.417 nM) and 0.152 
nM (CP-55,940 EC50 = 0.272 nM) for hCB2 (Inomata et al., 2017). Cannaert and co-workers, when 
employing an in vitro hCB1 and hCB2 receptor activation assay that included β-arrestin recruitment, 
determined a higher potency for AB-CHMINACA (hCB1 EC50 = 6.1 nM; hCB2 EC50 = 3.7 nM) than 
JWH-018 (hCB1 EC50 = 23.9 nM; hCB2 EC50 = 6.8 nM) (Cannaert et al., 2017). Franz et al., measured 
a CB1 receptor-mediated EC50 value of 0.278 nM (cAMP-Assay) for AB-CHMINACA in comparison to 
JWH-018 and MDMB-CHMICA with EC50 values of 1.132 and 0.142, respectively (Franz et al., 2017). 
TABLE 1 
Binding affinity (Ki), half maximal effective concentration (EC50) and efficacy (Emax) of AB-
CHMINACA and other synthetic cannabinoids as assessed with a GTPγS assay (data shown 
for CB1 receptor) (Wiley et al., 2015). 
Compound CB1 Ki [nM] EC50 [nM] Emax * 
CP-55,490 0.59 23.3 
124 
AB-CHMINACA 0.78 7.4 
205 
AB-PINACA 2.87 71 
108 
* Values represent percentage of maximal increase for [35S]GTPγS binding over basal at CB1 receptor 
As noted in Section A.1.1, the AB-CHMINACA that has been detected on the drug market might be 
contaminated with its N2-cyclohexylmethyl regioisomer. According to a recent comparative functional 
study with cloned human CB1 receptor preparation, AB-CHMINACA (that is the N1-alkylated isomer) 
is a full agonist and about 500-times more active than the partial agonist N1-alkylated isomer: the 
respective EC50 values are 7.8 and 4080 nM (Longworth et al., 2016). 
As it has been shown for ‘first generation’ synthetic cannabinoids (e.g. JWH-018, JWH-073) (Brents et 
al., 2011 and 2012) and for the THC metabolite 11-hydroxy-THC, it is likely that some of the mono-
hydroxylated metabolites of AB-CHMINACA retain activity at the CB1 receptor, which suggests that 
they might contribute to the pharmacological profile of the compound. Cannaert et al., (2017) 
determined in an in vitro receptor activity screen, using authentic human urine specimen confirmed to 
contain AB-CHMINACA metabolites that several metabolites retained the ability to activate 
cannabinoid receptors albeit at lower potency. However, in the case of CB1 receptor activity, it is 
unclear if the metabolites are able to cross the blood-brain-barrier and reach effective concentrations 
levels in the brain. For example, the amide cleavage product (a free carboxylic acid) shows only a low 
affinity towards the CB1 receptor (Ki: 380 nM) (Buchler et al., 2009).  
AB-CHMINACA is also a partial agonist at the CB2 receptor. Despite a high binding affinity (Ki: 0.45 
nM) the EC50 is rather low (232 nM) (Table 2) (Wiley et al., 2015). In contrast to CB1 receptors, CB2 
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receptors are mainly expressed on cells of the immune system and do not appear to contribute to 
psychoactivity. 
TABLE 2 
Binding affinity (Ki), half maximal effective concentration (EC50) and efficacy (Emax) of AB-
CHMINACA and other synthetic cannabinoids as assessed with a GTPγS assay (data shown 
for CB2 receptor) (Wiley et al., 2015). 
Compound CB2 Ki [nM] EC50 [nM] Emax * 
CP-55,490 0.30 2.1 63% 
AB-CHMINACA 0.45 232.4 35% 
AB-PINACA 0.88 14.9 41% 
* Values represent percentage of maximal increase for [35S] GTPγS binding over basal at CB2 receptor 
There are no data available on the effect of AB-CHMINACA on other pharmacological (receptor or 
enzyme) targets. The biological properties of its metabolites are also unknown. Assessment of ‘first-
generation’ synthetic cannabinoids (e.g. JWH-018, AM-2201, JWH-081) showed that binding to non-
cannabinoid receptors was weak or even absent for these compounds (Wiley et al., 2016). 
Pharmacokinetics 
AB-CHMINACA undergoes extensive metabolism in the human body. Like most synthetic 
cannabinoids it is not excreted unchanged in urine to a relevant extent. The main metabolic phase I 
reactions comprise mono-hydroxylations (e.g. at the cyclohexyl methyl moiety) and hydrolysis of the 
terminal amide function. Erratico et al., (2015) published a detailed investigation on the in vitro and in 
vivo metabolism of AB-CHMINACA. They identified several phase I metabolites formed by mono- and 
di-hydroxylation, desalkylation, as well as hydrolysis of the terminal and secondary amide function. 
Two glucuronidated forms of the metabolite formed by hydrolysis of the terminal amide function were 
detected in human urine. Wurita et al., (2016) reported quantitative data on the 4-hydroxy-cyclohexyl 
methyl metabolite (52.8 ± 3.44 ng/mL) and the hydrolysis product of the terminal amide function (41.3 
± 5.04 ng/mL) in human urine. AB-CHMINACA (2.2 to 1512.0 (mean = 299.2 pg/mg, median = 133.6 
pg/mg) could be identified in hair samples obtained from users and both primary and secondary 
amide hydrolysis products were also detectable in some of the hair samples (Sim et al., 2017). A 
single hydroxylated metabolite and its glucuronide conjugate were detected in mouse urine following 
intraperitoneal administration (3 mg/kg) of AB-CHMINACA (Wiley et al., 2015). AB-CHMINACA (7.61 
ng/mL) and the two hydrolysed metabolites (terminal amide: 56.73 ng/mL and secondary amide 
moiety: 2.29 ng/mL) were detected in blood samples taken from a fatal intoxication (Maeda et al., 
2017). Thirteen metabolites have been tentatively identified during the analysis of plasma, serum and 
urine samples that originated from 35 intoxication cases. The suggested biotransformations were 
hydroxylation of the cyclohexyl ring, hydrolysis of the terminal amide, hydrolysis of the secondary 
(“internal”) amide and hydroxylation/oxidation of the isopropyl group (Tyndall et al., 2015). The 
terminal carboxylic acid metabolite has also been detected in the urine of AB-FUBINACA users 
(Brajković et al., 2015). 
No further data on the pharmacokinetics of AB-CHMINACA are available in the literature. Self-
reported user experiences on the Internet have described an onset time of 1 to 5 minutes after 
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smoking with duration of the effect for 1 to 2 hours (22). As highlighted in the introduction, the 
assessment of such reports is problematic not least because users cannot confirm the actual 
substance used. 
Toxicology 
No studies were identified that have examined the toxicity of AB-CHMINACA. 
Data on cytotoxicity and genotoxicity of the structurally unrelated synthetic cannabinoids JWH-018, 
JWH-073, JWH-122, JWH-210, AM-694, AM-2201, UR-144, AKB-48-5F, AM-2201-IC, XLR-11 and 
RCS-4 have been published (Ferk et al., 2016; Koller et al., 2013, 2014 and 2015). Transferability of 
the results from other synthetic cannabinoids is very limited as individual compounds can show 
distinct toxicological profiles. 
Inter-individual genetic variability in metabolising enzymes 
No information specifically for AB-CHMINACA has been identified.  
Interactions with other substances and other interactions  
No studies were identified that have examined the interaction of AB-CHMINACA with other 
substances, including medicinal products. 
Effects on ability to drive and operate machines 
No studies of the effects of AB-CHMINACA on the ability to drive and operate machines have been 
performed. However, it is has been reported that intoxications caused by a range of synthetic 
cannabinoids, including AB-CHMINACA, significantly impair the mental and physical ability that is 
required to drive and operate machines (Section D1.2) (Capron, 2016; Griffiths and Griffin, 2016; 
Kaneko, 2017; Karinen et al., 2015; Musshoff et al., 2014; Peterson and Couper, 2015). 
Griffiths and Griffin report on 25 cases of suspected impaired driving in Queensland, Australia, in 
which AB-CHMINACA was detected in the blood samples of the drivers. The concentration in whole 
blood ranged from 2.4 to > 80 ng/g and in most of the cases AB-CHMINACA was the only drug 
consumed. The most commonly recorded symptoms of impairment were lane divergence, 
drowsiness, slurred speech, bloodshot eyes, confusion, impaired answers to questions and 
uncoordinated movement (Griffiths and Griffin, 2016). 
Peterson and Couper report on 33 suspected driving under the influence cases and drug recognition 
expert (DRE) cases in which AB-CHMINACA was detect in the blood samples. In 23 of these samples 
no further drug was detected. Drug recognition expert findings of impairment were reported in 10 of 
the 33 cases. The most common finding was extreme lane travel with near collisions and in nine 
cases the driver was found unconsciousness or slumped over the wheel. Horizontal gaze nystagmus 
was detected in 50 % and lack of convergence was observed in 30% of the DRE cases (Peterson and 
Couper, 2015). 
Analysis by UHPLC–MS/MS of the blood and/or urine of 1252 suspected drivers driving under the 
influence of drugs in 2014 and 2015 found that AB-CHMINACA was the most common synthetic 
cannabinoid (46 cases) with blood and urinary concentrations in the range of 0.27–22.6 and 0.5–3.79 
n/mL, respectively, when quantified (n = 10) (Institoris et al., 2017). 
                                                          
(22) http://drugs.tripsit.me/. Accessed: 30.06.2017 
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A3. Psychological and behavioural effects 
Animal in vivo and in vitro data 
Consistent with cannabinoid receptor activation under in vitro conditions, AB-CHMINACA was also 
found to induce cannabinoid/Δ9-THC-like properties in vivo. Wiley et al., (2015) confirmed that AB-
CHMINACA more potently (11- to 58-fold) induced rimobanant-reversible activity in the mouse tetrad 
test battery, i.e. leading to reduction in locomotor activity (ED50 = 1.8 μmol/kg; Δ9-THC ED50 = 104 
μmol/kg); antinociception (ED50 = 2.0 μmol/kg; Δ9-THC ED50 = 34 μmol/kg); hypothermia (ED50 = 1.1 
μmol/kg; Δ9-THC ED50 = 30 μmol/kg), and catalepsy (ED50 = 2.7 μmol/kg; Δ9-THC ED50 = 30 μmol/kg). 
Furthermore, AB-CHMINACA also fully substituted for Δ9-THC (training dose 5.6 mg/kg) in the drug 
discrimination assay (C57/BL6J mice), where AB-CHMINACA was determined to be ~17-fold more 
potent than Δ9-THC (ED50 = 0.34 μmol/kg; Δ9-THC ED50 = 5.5 μmol/kg) (Wiley et al., 2015). 
Human data 
While there is limited data, the psychological and behavioural effects of AB-CHMINACA appear to 
share some similarities with cannabis, THC, and other synthetic cannabinoids (e.g. Griffiths and 
Griffin, 2016; Peterson and Couper, 2015; See also Section D). This includes: relaxation, euphoria, 
lethargy, confusion, anxiety, fear, distorted perception of time, depersonalisation, hallucinations, 
paranoid inclusions, as well as dry mouth, bloodshot eyes, tachycardia, nausea, vomiting and 
impaired motor performance. These effects appear to be much more pronounced and severe when 
compared to cannabis (Ford et al., 2017; Zaurova et al., 2016). In addition, psychotic episodes, as 
well as aggressive and violent behaviour, have also been reported. (See also Section D1 and Section 
D3.4.) 
A4. Legitimate uses of the product  
AB-CHMINACA is used as an analytical reference material in clinical and forensic case 
work/investigations as well as scientific research. There is currently no information that suggests AB-
CHMINACA is used for other legitimate purposes. 
There are no reported uses of AB-CHMINACA as a component in industrial, cosmetic or agricultural 
products. In addition, a search of the Registration, Evaluation, Authorisation and Restriction of 
Chemicals (REACH) registered substances database hosted by the European Chemicals Agency 
(ECHA) using the CAS Registry Number listed in Section A1.1 returned no results. 
There is no marketing authorisation (existing, on-going or suspended) for AB-CHMINACA neither in 
the European Union nor in the Member States that responded to the request for information from the 
European Medicines Agency, which was undertaken as part of the Joint Report process (EMCDDA, 
2017c). 
There is no information to suggest that AB-CHMINACA is currently used in the manufacture of a 
medicinal product in the European Union. However, in the absence of a database on the synthetic 
routes of all medicinal products it is not possible to confirm whether or not AB-CHMINACA is currently 
used in the manufacture of a medicinal product.  
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Section B. Dependence and abuse potential 
B1. Animal data  
No data from animal studies regarding AB-CHMINACA are available in the literature in respect to 
dependence potential. Studies conducted with JWH-018 and JWH-073 in rats and monkeys suggest 
cannabinoid-like effects in the drug discrimination paradigm (Ginsburg et al., 2012; Järbe et al., 2010 
and 2011). Though no specific data exist for AB-CHMINACA, it is possible that the substance might 
show similar properties. As noted above, AB-CHMINACA more potently induced Δ9-THC-like 
responses in the mouse tetrad assays, and fully substituted for Δ9-THC in a drug discrimination 
assay. This suggests an overlap in the mechanism of action (Wiley et al., 2015), and, thus, AB-
CHMINACA might show potential for abuse liability.  
B2. Human data  
No studies were identified that have investigated the dependence and/or abuse potential of AB-
CHMINACA in humans.  
It has been suggested that consumption of synthetic cannabinoids can produce tolerance and 
withdrawal-like symptoms when use is discontinued following a regular use (Cooper, 2016, 
Macfarlane and Christie, 2015, Van Hout and Hearne, 2017; Zimmermann et al., 2009).  
Two cases of withdrawal-like symptoms following use of AB-CHMINACA have been reported to the 
Poisons Information Centre Freiburg, Germany (23). 
Withdrawal-like symptoms following cessation of synthetic cannabinoid have been described in the 
literature. These include: anxiety, unstable mood, crying fits, feeling of inner emptiness, spatial 
disorientation, hyperacusis (increased sensitivity to ordinary environmental sounds), somatic pain, 
shortness of breath, hyperventilation, intense sweating and sensations of motor and inner 
restlessness (Hermanns-Clausen et al., 2012; Hermanns-Clausen et al., 2013). 
Section C. Prevalence of use 
Information from seizures, collected and biological samples 
AB-CHMINACA was formally notified 10 April 2014 by the EMCDDA on behalf of Latvia, in 
accordance with Article 4 of the Council Decision. The Reporting Form details a seizure of 8 bags of 
herbal material with a total weight of 3.81 grams, seized in February 2014 by the Municipal Police. 
The identification was initially based on GC-MS analysis performed by the Forensic Service of the 
State Police, followed by NMR confirmation performed at the Latvian Institute of Organic Synthesis. 
Since then, a total of 24 Member States, Norway, and Turkey have reported detections of AB-
CHMINACA (24) (EMCDDA, 2017c). 
                                                          
(23) Personal communication to Volker Auwärter. 
(24) ‘Detections’ is an all-encompassing term and may include seizures and/or collected and/or biological samples that are 
analytically confirmed. Seizure means a substance available (seized) through law enforcement activities (police, customs, 
border guards, etc.). Collected samples are those that are actively collected by drug monitoring systems (such as test 
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Detections of AB-CHMINACA may well be under-reported since the substance is not routinely 
screened for. Three Member States (Austria, Slovenia and Sweden) and Norway reported that AB-
CHMINACA is part of routine screening in some (but not all) of their laboratories. 
Information from seizures 
A total of 26 countries reported seizures (25) of AB-CHMINACA to the EMCDDA and/or Europol.  
Information reported to the EMCDDA and Europol indicates that 6422 seizures of AB-CHMINACA 
have been reported by: Austria (10 seizures), Belgium (24), Bulgaria (17), Croatia (45), Denmark (2), 
Estonia (18), Finland (114), France (26), Germany (2), Greece (3), Hungary (1723), Italy (1), Latvia 
(221), Lithuania (62), Luxembourg (4), the Netherlands (7), Poland (1793), Portugal (3), Romania (3), 
Slovakia (6), Slovenia (2), Spain (7), Sweden (121), the United Kingdom (398), Turkey (1801), and 
Norway (9). 
Physical forms seized were typically herbal/plant materials. There were also notable large seizures of 
powders. To a lesser extent, liquids and blotters were also seized. 
The majority of the seizures comprise police and customs cases, with additional seizures taking place 
in custodial settings.  
Herbal material 
4066 seizures of AB-CHMINACA in herbal material were reported by 24 countries: Austria, Bulgaria, 
Croatia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Italy, Latvia, Lithuania, 
Luxembourg, the Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, the 
United Kingdom, and Norway. These amounted to over 40 kg as well as more than 145,000 packages 
of commercially labelled herbal smoking mixtures (26) that weighed 1–3 g each. In addition, Turkey 
reported 1757 seizures of herbal material amounting to almost 150 kg (27).  
The largest single seizure of AB-CHMINACA in herbal material was reported by Spain, as part of the 
law enforcement operation codenamed ‘Operation Alimaya’. This large-scale operation was carried 
out in Alicante in March 2016. A total of 145,157 packages (of 1–3 g each, also containing the 
synthetic cannabinoids AMB-FUB and AB-FUBINACA) and 2 bags (of 2 kg each, containing also 
AMB-FUB) were seized.  
Other large single seizures of herbal materials were reported by Lithuania (3.9 kg in the form of 
briquettes with Euro signs, seized by Police) and Bulgaria (2 kg, no further information).  
Hungary reported around 1700 seizures of herbal material amounting to 16 kg.  
In herbal material, AB-CHMINACA was commonly found mixed with other synthetic cannabinoids. In 
15 seizures, stimulants were also detected: Hungary (8 cases; amphetamine, pentedrone, 
clephedrone) and Poland (7 cases; amphetamine, α-POP and clephedrone).  
                                                                                                                                                                                    
purchases) for monitoring and research purposes. Biological samples are those from human body fluids (urine, blood, etc.) 
and/or specimens (tissues, hair, etc.) 
(25) Many ‘seizures’ relate to individual case-level data, however, some data provided to the EMCDDA are aggregated at the 
country level. Data is drawn from the Joint Report Questionnaires and data provided in the bi-annual data gathering (EU Early 
Warning System progress and final reports) and from individual Reporting forms submitted on an ad hoc basis. 
(26) Products seized include: ‘Aromatic Pot Pourri’, ‘Jamaican Gold Supreme’, ‘Jamaican Gold Extreme’, ‘Yama’, ‘Bonzai 
Summer Boost’, ‘Bonzai Winter Boost’, ‘Bonzai Citrus’, ‘Blaze’, ‘Bubblegum’, ‘Manga Xtreme’, ‘Manga XXL’, ‘V.I.P.’, ‘Love’, 
‘R&B’, and ‘King Size Slim Rolling Papers’. 
(27) Minimum estimate provided by the Turkish national focal point for 2016. 
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Quantitative information on the purity of AB-CHMINACA in 8 analysed samples of herbal material was 
provided by Lithuania and in one sample where the physical form was not specified. The 
concentration of AB-CHMINACA in the samples was in the range of 0.15–4.3 % (mean: 1.97 %, 
median: 2.0 %). 
Powders 
281 seizures of powder were reported by 22 countries: Austria, Belgium, Bulgaria, Denmark, Estonia, 
Finland, France, Germany, Hungary, Latvia, Lithuania, Luxembourg, the Netherlands, Norway, 
Poland, Romania, Slovakia, Slovenia, Spain, Sweden, Turkey and the United Kingdom, amounting to 
a total of more than 43.8 kg.  
A number of large single customs seizures of AB-CHMINACA in powder form were reported, such as: 
i. 4.8 kg of powder seized by customs in a FedEx delivery, reported by Luxembourg;  
ii. 3.5 kg of white powder seized at Roissy Airport, France (originating from China and destined 
for Austria); and, 
iii. 2 kg of powder seized at Madrid-Barajas Airport, Spain (originating from China and destined 
for France). 
Liquids 
Seizures of AB-CHMINACA in liquid form were reported by Sweden (4 cases) and Finland (3), 
amounting to a total of 293 ml. The largest seizure was reported by Finland and consisted of 50 
bottles (225 ml) of “e-liquid” for vaping, with a reported concentration of 3.5 mg/ml).  
Blotters 
178 seizures (193.9 g) of AB-CHMINACA in blotter form were reported by Poland. 
Other physical forms 
Lithuania reported 2 seizures, amounting to more than 20 kg where no information on the physical 
form was available.  
Information from collected samples 
Two collected samples of AB-CHMINACA were reported to the EMCDDA from Belgium and Poland. 
The case from Belgium involved a sample of white powder found to contain AB-CHMINACA, collected 
from a patient who had used the substance and subsequently required medical treatment at hospital. 
A bag of herbal material containing AB-CHMINACA was reported by Poland, with the synthetic 
cathinone α-PVP also detected in the sample. 
Information from biological samples 
Serious adverse events (deaths and acute intoxications) with confirmed exposure to AB-CHMINACA 
from biological samples are discussed in Section D. 
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Additionally, a total of 551 analytically confirmed detections of AB-CHMINACA in biological samples 
were reported (28) by three Member States: Hungary (537 cases), Sweden (10) and Poland (4).  
A large majority of these cases (484) related to drug abuse (consumption), intoxication or non-fatal 
intoxication, with no further details specified. In addition, 52 cases were related to persons suspected 
of driving under the influence of drugs (including 10 traffic accidents), all reported by Hungary. The 
type of event was not specified in 15 of the cases.  
Availability, supply, price 
Information on production 
No information was received in relation to the production of AB-CHMINACA. 
Information on trafficking 
Information related to trafficking routes is limited to the seizures reported above. Large shipments 
containing AB-CHMINACA in powder form, that were intercepted by customs officials in France and 
Spain, originated in China. Information reported to Europol is limited to seizures made by Bulgarian 
customs of shipments containing AB-CHMINACA arriving from Spain and the Netherlands.  
Availability from Internet vendors 
Table 3 provides the results of an search for online shops on the surface web selling research 
chemicals in various countries (Belgium, Czech Republic, Germany, Hungary, The Netherlands, 
Poland, Portugal, Spain, Sweden, United Kingdom, Canada, United States, and, China; allocation 
based on entries at reddit.com). Fifty-seven shops were screened for their product portfolio. Seven of 
the shops listed AB-CHMINACA on their website. The compound was listed as ‘out of stock’ in six of 
these shops. The table also lists the price range for the compound depending on the order quantity. 
TABLE 3  
Prices of AB-CHMINACA depending on the order quantity from 7 surface web vendors. 
 1 g 10 g 100 g 1000 g 
Number of products 5 4 4 1 
Range 9.38–21.99 EUR 130–159 EUR 790–912 EUR N/A 
Median 21.99 EUR 154 EUR 859 EUR N/A 
Mean 21.99 EUR 150.20 EUR 855.8 EUR 5127 EUR 
It is important to note that AB-CHMINACA has been controlled in China since October 2015. While 
some of the vendors that appear to be based in China still list AB-CHMINACA on their websites, they 
usually do not ship the compound to Germany (29). 
 
                                                          
(28) Turkey reported 902 detections of AB-CHMINACA in biological samples (blood, hair and urine) which may contain 
duplicates and therefore have not been included in the total count above. 
(29) Observations based on test purchases from such sites. Personal Communication from Volker Auwärter.  
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Prevalence of use  
No studies were identified that have investigated the prevalence of use of AB-CHMINACA in the 
general population.  
Similar to other synthetic cannabinoids, AB-CHMINACA is often sold and used as a ‘legal’ substitute 
for cannabis, typically as herbal smoking mixtures (EMCDDA, 2009; EMCDDA, 2017a). The 
composition of these products varies over time, with substances being changed in response to, or, in 
anticipation of, the introduction of control measures. This may have implications on the availability of 
AB-CHMINACA and its prevalence of use. Overall, the available information does not suggest 
widespread use of the substance (30). 
Because of the variability in the composition of smoking mixtures, and the fact that the ingredients are 
not typically disclosed, most users will be unaware that they are using AB-CHMINACA. As a result, 
the prevalence of use of AB-CHMINACA should be considered in the wider context of the prevalence 
of use of herbal smoking mixtures, commonly referred to as ‘spice’. 
The use of ‘spice’-like products has been studied in some European countries in general population 
surveys or in specific populations such as students, ‘clubbers’ and/or internet users. The results of 
these surveys are not comparable as they use different methodology and samples but overall they 
indicate generally low prevalence levels in these groups (EMCDDA, 2017a). 
There is evidence that in some groups, such as high risk drug users and other marginalised groups, 
the prevalence of use of synthetic cannabinoids, particularly as smoking mixtures, may be higher. 
This includes individuals who are subject to drug testing (such as people in drug treatment, prisoners, 
and drivers) because some drug tests/screens will be unable to detect synthetic cannabinoids. In 
addition some vulnerable populations, such as the homeless and prisoners, specifically seek out 
synthetic cannabinoids because they have a reputation for causing profound intoxication, they can be 
cheap and are easy to smuggle(EMCDDA, 2017a; Blackman and Bradley, 2017; HMIP, 2015; Ralphs 
et al., 2017; User Voice, 2016). 
Section D. Health risks 
D1. Acute health effects 
D1.1. Animal data 
With the exception of the data published by Wiley et al., (2015) that demonstrated that AB-
CHMINACA can induce cannabinoid/Δ9-THC-like properties in vivo, no other animal data were 
identified that have examined the acute health effects of the substance. 
D1.2. Human data 
No clinical studies were identified that have examined the acute health effects of AB-CHMINACA 
and/or its metabolites in humans. Data from serious adverse events associated with AB-CHMINACA 
                                                          
(30) Based on the product monitoring within the EU-projects ‘SPICE II Plus’ and ‘SPICE Profiling’ and the results from serum 
and urine analysis conducted at the Institute of Forensic Medicine Freiburg, Germany, it appears that the prevalence of AB-
CHMINACA in Germany increased in the last quarter of 2014, reached its maximum in the first half of 2015 and decreased 
since the third quarter of 2015. In the first half of 2015 AB-CHMINACA was detected in 30% of all ‘legal high’ products analysed 
(n = 217). AB-CHMINACA was detected in 36% of all serum samples positive for synthetic cannabinoids (n = 186, total number 
of samples analysed n = 634) in the same time period. 
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are discussed below. In general, the acute health risks associated with AB-CHMINACA appear to be 
similar to those found with other synthetic cannabinoids. 
As synthetic cannabinoids activate the CB1 receptor in a similar way to THC, their effects appear to 
have some similarities with cannabis (Auwärter et al., 2009). This includes: relaxation, euphoria, 
lethargy, confusion, anxiety, fear, distorted perception of time, depersonalisation, hallucinations, 
paranoid inclusions, as well as dry mouth, bloodshot eyes, tachycardia, nausea, vomiting and 
impaired motor performance. These effects appear to be much more pronounced and severe when 
compared to cannabis (Ford et al., 2017; Winstock et al., 2013; Zaurova et al., 2016). 
Severe and fatal poisoning also appears to be more common with synthetic cannabinoids as 
compared to cannabis. This can include severe cardiovascular toxicity (including sudden death), 
severe central nervous system depression (such as rapid loss of consciousness/coma), respiratory 
depression, seizures and convulsions, hyperemesis, delirium, agitation, psychosis, and aggressive 
and violent behaviour (Adams et al., 2017; Brenneman et al., 2016; Capron, 2016; Ford et al., 2017, 
Hermanns-Clausen et al., 2013; EMCDDA, 2017c, EMCDDA, 2017d, EMCDDA, 2017e; EMCDDA, 
2017f; EMCDDA, 2017g; Kasper et al., 2015; Pap, 2016; Schwartz et al., 2015; Shevyrin et al., 2015; 
Springer et al., 2016; Tait et al., 2016; Trecki et al., 2015; Tyndall et al., 2015; Waugh et al., 2016; 
Winstock et al., 2013; Zaurova et al., 2016). (See Section D3.4.) 
In addition, some of the features of poisoning—particularly loss of consciousness, respiratory 
depression, and behavioural effects—may place users at additional risks, such as choking 
on/aspirating vomit, drowning, falling, hypothermia as a result of falling unconscious outside in cold 
weather, and self-inflicted violence/injury (EMCDDA, 2017g; Tait et al., 2016; Yeter, 2017). The 
aggressive and violent behaviours reported with synthetic cannabinoids may also place others at risk 
of injury. 
Overall, poisoning with synthetic cannabinoids may be made worse when other drugs, especially 
central nervous system depressants (such as alcohol, opioids, and sedative/hypnotics), are used at 
the same time.  
There is no approved antidote to poisoning caused by synthetic cannabinoids. 
Acute intoxications reported by the Member States 
A total of 7 acute intoxications with confirmed exposure to AB-CHMINACA were reported to the 
EMCDDA by Belgium (1 case), France (1), Hungary (3), and the United Kingdom (2). The cases 
occurred between 2014 and 2016. No further details are available on the cases from Hungary.  
In 2 out of the remaining 4 cases, no other substances were detected. In the other 2 cases other 
substances detected included synthetic cannabinoids and an opioid. In all 4 cases, the clinical 
features of the poisoning were typical of those reported for synthetic cannabinoids. 
Acute intoxications identified from other sources 
Angerer et al., have reported a case in which AB-CHMINACA and MDMB-CHMICA was detected in 
the serum samples (0.28 ng/mL & 0.45 ng/mL, respectively) and the patient did not show any 
symptoms (Angerer et al., 2016). 
In an observational study of 18 patients with analytically confirmed synthetic cannabinoid toxicity in 
London, United Kingdom, seizures and agitation were mentioned as clinical features observed in 
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three acute intoxication cases shown to involve exposure to AB-CHMINACA (Abouchedid et al., 
2017). In one of these cases, AB-CHMINACA was the only substance detected. The male patient (29 
years) suffered from agitation and seizures; admission observation: heart rate 123 bpm; Glasgow 
Coma Score 13; temperature 34.6 °C. The patient’s length of stay was 14.8 h (Abouchedid et al., 
2017). 
A series of acute delirium (n = 24) and seizures (n = 14) was encountered in 35 patients between 28 
May 2014 and 8 June 2014 in Florida, United States, (median age was 34.6 years (range, 14–58); 31 
male, 4 female) reported symptoms included altered mental status (61%, n = 24), hallucinations (6%, 
n = 2), and seizures (40%, n = 14). None of the patients were hyperthermic. Clinical presentations: 
patients requiring intubation (14.3%, n = 5), seizures (40%, n = 14), intensive care unit submission 
(20%, n = 7), initial tachycardia (heart rate >100) (45.7%, n = 16), initial hypertension (systolic >150 or 
diastolic >90) (17.1%, n = 6), altered mental status (Glasgow Coma Score ≤14) (54.3%, n = 19). 
Forty-five samples from 26 cases were available for analysis and 15 cases were confirmed AB-
CHMINACA exposures. In some instances, plasma, serum and urine samples were available (Tyndall 
et al., 2015).  
Other cases of intoxications associated with AB-CHMINACA occurring in various other cities in the 
United States have been reported. No specific details on these cases were reported (Trecki, Gerona 
and Schwartz, 2015). 
In a prospective study of patients treated in emergency departments after use of synthetic 
cannabinoids in Germany, AB-CHMINACA was identified in 20 serum samples and in 21 urine 
samples (Hermanns-Clausen et al., 2017). Concentration in serum varied from trace amounts (0.1 
ng/mL) up to 27 ng/mL. The most frequent clinical symptoms were central nervous system depression 
(in 13 out of 20 patients), tachycardia (in 10 out of 20 patients) and disorientation (in 9 out of 20 
patients). No correlation between serum level of AB-CHMINACA and the severity of poisoning was 
observed.  
Deaths reported by the Member States 
A total of 31 deaths with confirmed exposure to AB-CHMINACA were reported to the EMCDDA by 
Croatia (1 case), Germany (4), Hungary (11), Poland (2), Sweden (5), and the United Kingdom (8). In 
all cases, exposure to AB-CHMINACA (or an associated metabolite in one case) was analytically 
confirmed from post-mortem samples.  
The deaths occurred between 2014 and 2017. 
Demographic data were available for all but 6 deaths and involved 24 males (77%) and 1 female 
(3%). The mean age of the males was 30 years (median 27) and ranged from 16 to 66 years. The 
female was 38 years old. 
Circumstances and cause of death 
There was a lack of information regarding any symptoms experienced by the deceased prior to death 
in the majority of cases, but, in one case, the deceased was described to have vomited and became 
hypothermic and unconscious. Where information was known, in the majority of instances the 
individuals were found dead, predominantly in a home environment (either their own or a friend’s), or 
outside; 2 of the deaths occurred in prison. Consequently, it was not possible to identify or evaluate 
ante-mortem symptoms (especially in relation to acute intoxication) in these cases. 
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A cause of death was reported in 22 cases, and, in at least 9 deaths, AB-CHMINACA was either the 
cause of death or is likely to have contributed to death (even in presence of other substances); other 
substances were detected in 25 cases. AB-CHMINACA was the only drug present in 6 deaths based 
on additional toxicological information, where available. 
AB-CHMINACA was quantified in 11 cases. Post-mortem blood concentrations between 0.32 and 12 
ng/mL (median 3.70 ng/mL), or equivalent, were recorded. Due to the toxicity of potent synthetic 
cannabinoids, a post-mortem blood concentration cannot necessarily be used to determine a “fatal” 
concentration. In the majority of circumstances involving synthetic cannabinoids, the mere presence 
of the drug is of significance whether concentration has been determined or not, especially in 
situations of poly-drug use and the varying circumstances in which they are used. 
A range of other substances were detected in the deaths, including: alcohol, cannabinoids, 
antidepressants, antipsychotics, cocaine, zopiclone, synthetic cathinones, opiates/opioids (morphine, 
buprenorphine, acetylfentanyl, tramadol, methadone, codeine) and benzodiazepines. Other synthetic 
cannabinoids and/or metabolites were detected in 6 of the deaths, including; MDMB-CHMICA, 5F-
MDMB-PINACA, ADB-CHMINACA, FUB-AKB-48, 5F-PB-22, UR-144. 
Overall, whilst other substances may have contributed some toxicity, the potent nature of AB-
CHMINACA means the primary toxic contribution could be attributed to the drug and death may not 
have occurred if AB-CHMINACA had not been used. However, in the cases where multiple synthetic 
cannabinoids were present, it is not necessarily possible or appropriate to identify AB-CHMINACA as 
the primary synthetic cannabinoid that may have produced toxicity but a synergistic effect is likely 
nonetheless. Sufficient case data were available in 29 of the 31 deaths. An assessment of the 
toxicological significance score (TSS) (Elliott, Sedefov, and Evans-Brown, 2017) incorporating the 
above considerations in the deaths, showed that AB-CHMINACA had a TSS value of 3 (high) in 18 
deaths (where it was cited as the cause of death or is likely to have contributed to death following 
assessment). In the remaining 11 deaths, there was an alternative cause of death (such as hanging, 
drowning, stabbing, other drug overdose, or other physiological cause) (TSS value of 1, low). 
However, there is a possibility that use of AB-CHMINACA could have contributed to some of these 
situations/causes but there was insufficient circumstance and other information to allow this 
attribution. 
Deaths identified from other sources 
There are only limited data published in the scientific literature regarding fatalities following confirmed 
exposure to AB-CHMINACA. 
Hess et al., reported a death where AB-CHMINACA was detected in femoral blood along with ten 
other synthetic cannabinoids. The cause of death was determined to be diabetic ketoacidosis and the 
authors state that the death could have been induced by skipping of insulin doses due to the 
intoxicated state or by the synthetic cannabinoids, which were described to be able to produce 
hyperglycaemia themselves (Hess et al., 2015). 
Hasegawa et al., report on a death involving the synthetic cannabinoids AB-CHMINACA and 5F-AMB, 
as well as the NMDA receptor channel blocker diphenidine. The deceased was found in a prone 
position in a car with a lighter in his hand and an opened package of herbal blend (later confirmed to 
contain diphenidine) lying below his chest and a second package (later confirmed to contain AB-
CHMINACA and 5F-AMB) on the backseat. Based on the high concentrations of diphenidine in the 
post-mortem tissue the authors suggested that this drug played a major role in the cause of death. 
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AB-CHMINACA was detected in multiple tissues and 5F-AMB was only detected in the adipose tissue 
in this case (Hasegawa et al., 2014). 
Maeda et al., reported a case of sudden death linked to non-cardiogenic severe pulmonary oedema 
and hypoxia. AB-CHMINACA (7.61 ng/mL) and the terminally and internally hydrolysed carboxylic 
acid metabolites (56.73 and 2.29 ng/mL, respectively) were detected in blood; AB-FUBINACA (0.11 
ng/mL), FUB-PB22, and 5F-AMB (both below the limit of quantitation) were also detected (Maeda et 
al., 2017). 
A male in his thirties was found dead in his car parked at a supermarket parking lot. AB-CHMINACA 
was detected in urine (232 pg/mL) (Minakata et al., 2017). 
There are no data available in the literature regarding the post-mortem stability of AB-CHMINACA. 
However, it has been observed that structurally similar synthetic cannabinoids might undergo 
hydrolysis during the post-mortem interval (Moosmann et al., 2017). Consequently, analytical 
methods solely targeting the parent compounds (as it is the case for most serum/blood screening 
methods) might miss AB-CHMINACA detection in cases where a long post-mortem interval is involved 
or if the samples are stored for a longer period of time prior to analysis. 
D2. Chronic health effects 
D2.1. Animal data 
No studies were identified that have investigated the chronic health effects of AB-CHMINACA in 
animals. 
D2.2. Human data 
No studies were identified that have investigated the chronic health effects of AB-CHMINACA in 
humans. 
D3. Factors affecting public health risks 
D3.1. Availability and quality of the new psychoactive substance on the market  
AB-CHMINACA has been sold on the surface web as a powder and in ‘legal-high’ type products such 
as herbal smoking mixtures. The substance is available in small and wholesale amounts. Herbal 
smoking mixtures do not commonly state the presence of synthetic cannabinoids. As a result, many 
users will not be aware that they are using such substances. 
D3.2. Availability of the information, degree of knowledge and perceptions amongst users 
concerning the psychoactive substance and its effects 
The availability of information, degree of knowledge and perceptions amongst users concerning AB-
CHMINACA and its effects are limited. There is considerable variability both within and between 
different batches of synthetic cannabinoid products, in terms of both the substances and the amount 
present. For that reason, most individuals will be unaware that they are using AB-CHMINACA.  
Unknown to users, synthetic cannabinoids have also been sold as ecstasy/MDMA and other illicit 
drugs. In some cases, this has led to severe poisoning (Allibe et al., 2016; Brenneman et al., 2016; 
Pap, 2016).  
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Opioids (such as U-47,700 and furanylfentanyl) have also been identified in smoking mixtures/plant 
material. Users will be unaware of this, and the use of such opioid-containing products could pose a 
risk of life-threatening respiratory depression. This risk will be especially high in individuals with no 
tolerance to opioids (Coopman et al., 2017; EMCDDA, 2017h). 
D3.3. Characteristics and behaviour of users  
No studies were identified that have examined the characteristics and behaviour of users of AB-
CHMINACA.  
Synthetic cannabinoids are sold and used as a ‘legal’ replacement for cannabis (EMCDDA, 2009; 
EMCDDA, 2017a). In addition some users specifically seek out synthetic cannabinoids because they 
have a reputation for causing profound intoxication, they can be cheap and are easy to smuggle. In 
most cases they are smoked using a cigarette of plant material that has been mixed with one or more 
of the cannabinoids. Because these products rarely state the ingredients, most users will be unaware 
that they are using synthetic cannabinoids. 
People who use synthetic cannabinoids may include recreational users (including cannabis users), 
high-risk drug users, and groups who experiment with the substances (such as psychonauts). They 
may also include individuals who are subject to drug testing (such as people in drug treatment, 
prisoners, and drivers) because some drug tests/screens will be unable to detect some of the 
cannabinoids (especially those that are relatively new to the drug market). In the past few years, 
synthetic cannabinoids have become increasingly used by vulnerable groups (such as the homeless 
and prisoners). 
D3.4. Nature and extent of health consequences 
The limited information available on the pharmacology, dependence and abuse potential, and acute 
health effects of AB-CHMINACA have been discussed above (Section A2, Section B, Section D1 and 
Section D2).  
Compared to cannabis, more pronounced effects as well as severe and fatal poisoning appear to be 
more common with synthetic cannabinoids (EMCDDA, 2017c; EMCDDA, 2017d, EMCDDA, 2017e, 
EMCDDA, 2017f, EMCDDA, 2017g; Tait et al., 2016; Waugh et al., 2016; Winstock et al., 2013; 
Zaurova et al., 2016). The reasons for this are poorly understood, but at least two factors are likely to 
be important: the high potency of the substances and the unintentionally high doses that users are 
exposed to. 
Firstly, studies have found that many of the cannabinoids, including AB-CHMINACA, which are sold 
on the drug market, are much more potent and active, typically behaving as full agonists, as 
compared to THC. This means that even at very small doses they can activate the CB1 receptor much 
more strongly than THC (Banister et al., 2016; Ford et al., 2017; Reggio, 2009; Tai and Fantegrossi, 
2017). 
Secondly, the process for mixing the synthetic cannabinoids with the herbal/plant material (which are 
the most common way of using these substances) can lead to dangerous amounts of the substances 
in the products. This is because producers have to guess the amount of cannabinoids(s) to add, while 
the mixing process makes it difficult to dilute the substances sufficiently and distribute them 
consistently throughout the plant material. This can result both in products that contain toxic amounts 
of the substances in general (Ernst et al., 2017; Frinculescu et al., 2016; Langer et al., 2014: Langer 
et al., 2016), as well as products where the cannabinoids are clumped together forming highly 
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concentrated pockets within the plant material (Frinculescu et al., 2016; Moosmann et al., 2015; 
Schäper et al., 2016). These issues are made worse as the products are typically smoked allowing 
the substances to be rapidly absorbed into the systemic circulation (bloodstream) and to reach the 
brain. 
The combination of these two factors makes it difficult for users to control the dose that they are 
exposed to and can lead them to rapidly administer a toxic dose unintentionally. Accounts from 
patients and people who witness poisonings suggest that in some cases a small number of puffs from 
a cigarette have been sufficient to cause severe and fatal acute poisoning.  
These two factors are also responsible for outbreaks of mass poisonings caused by smoking 
mixtures, which have ranged in size from four or five victims to over 800. Mass poisonings can 
overwhelm emergency responders and other local healthcare systems. Many of the outbreaks that 
have been reported so far are from the United States, but they have also occurred in Russia and 
Europe (Adams et al., 2017; Kasper et al., 2015; Schwartz et al., 2015; Shevyrin et al., 2015; Springer 
et al., 2016; Trecki et al., 2015; Tyndall et al., 2015). Such types of outbreaks have been reported for 
AB-CHMINACA (Trecki et al., 2015; Tyndall et al., 2015). 
Driving while under the influence of synthetic cannabinoids places users and others at risk of injury 
(Capron, 2016; Kaneko, 2017; Karinen et al., 2015; Musshoff et al., 2014; Peterson and Couper, 
2015). In a recent case series of 36 drivers suspected of driving under the influence of drugs in 
Washington, United States, where 5F-MDMB-PINACA was the predominate psychoactive substance 
identified, 50% of the drivers were found unconscious and 28% has been involved in collisions with 
single/multiple cars (Capron, 2016). Similarly, the operation of machinery while under the influence of 
synthetic cannabinoids may place the user and others at risk of injury. 
D3.5. Long-term consequences of use 
While there is limited data for AB-CHMINACA, the long-term consequences of use might share 
similarities to cannabis and other synthetic cannabinoids. This may include dependence. 
D3.6. Conditions under which the new psychoactive substance is obtained and used, including 
context-related effects and risks 
There is limited data on the conditions which AB-CHMINACA is obtained and used. 
Sources appear to include internet retailers, physical shops, friends and other acquaintances, and 
street-level drug dealers (Section D3.1). In addition, most users will be unaware that they have 
sourced and used AB-CHMINACA (Section C and Section D1.2.1). The available data suggests that 
AB-CHMINACA is used in the same environments as cannabis, including the home, and, to a lesser 
extent, in recreational settings.  
Section E. Social risks 
The available data suggests that the acute behavioural effects of AB-CHMINACA bear some 
similarities to cannabis but are more pronounced and severe. 
In addition, and, of particular note, is that in some settings, synthetic cannabinoids are increasingly 
used by high risk drug users and other vulnerable groups, such as the homeless and prisoners. In at 
least some cases, these users are specifically seeking out synthetic cannabinoids because the 
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substances have developed a reputation for causing profound intoxication, they can be cheap and are 
easy to smuggle. Reports suggest that this has exacerbated existing health and social problems for 
these vulnerable groups, as well as creating new ones.  
E1. Individual social risks 
There is no information on whether the use of AB-CHMINACA causes individual social risks; however, 
they may have some similarities with those associated with other synthetic cannabinoids. These may 
impact on education or career, family or other personal and social relationships and may result in 
marginalisation. 
E2. Possible effects on direct social environment  
While there is no specific information on the possible effects of AB-CHMINACA on the direct social 
environment, the behavioural effects of synthetic cannabinoids include reports of aggressive and 
violent behaviour. This may place users and others at risk of injury. 
E3. Possible effects on society as a whole 
There is no specific information on the possible effects of AB-CHMINACA on society as a whole. 
E4. Economic costs 
There are no data on the effects of AB-CHMINACA on economic costs. 
E5. Possible effects related to the cultural context, for example marginalisation 
There is no specific data on the possible effects of AB-CHMINACA related to the cultural context.  
Of particular note is that synthetic cannabinoids are increasingly used by vulnerable groups, such as 
the homeless and prisoners. Reports suggest that this has caused new health and social problems as 
well as exacerbated existing ones for these groups. For example, in prisons, alongside the adverse 
health effects, the market in synthetic cannabinoids has been linked to an increase in aggression, 
violence, bullying, and debt. In some cases this has caused a serious threat to the overall safety and 
security of the prison environment (Blackman and Bradley, 2017; HMIP, 2015; Ralphs et al., 2017; 
User Voice, 2016). 
E6. Possible appeal of the new psychoactive substance to specific population groups 
within the general population 
While no specific examples are available on the possible appeal of AB-CHMINACA to specific user 
groups, it is reasonable to assume AB-CHMINACA may be sought by those looking for ‘legal’ 
substitutes for cannabis. This includes individuals subject to drug testing (such as drivers, prisoners, 
those in drug treatment, and those subject to workplace drug testing), as commonly used drug tests 
may be unable to detect the compounds (Gunderson et al., 2014; Vandrey et al., 2012). 
In addition, and, of particular note, is that synthetic cannabinoids are increasingly used by high risk 
drug users and other vulnerable groups, such as the homeless and prisoners. In at least some cases, 
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these users are specifically seeking out synthetic cannabinoids because they have developed a 
reputation for causing profound intoxication, they can be cheap and are easy to smuggle. Reports 
suggest that this has exacerbated existing health and social problems as well as creating new ones 
for these groups. For example, in prisons, alongside the adverse health effects, the market in 
synthetic cannabinoids has been linked to an increase in aggression, violence, bullying, and debt. In 
some cases this has caused a serious threat to the overall safety and security of the prison 
environment (Blackman et al., 2017; HMIP, 2015; Ralphs et al., 2017; User Voice, 2016). 
Section F. Involvement of organised crime 
F1. Evidence that criminal groups are systematically involved in production, trafficking 
and distribution for financial gain 
There is no specific information to suggest the involvement of organised crime or established criminal 
groups in the manufacture, distribution and supply of AB-CHMINACA. 
In the cases where the origin of the seizures reported to Europol was known, the country of origin 
indicated was: Spain (1) and the Netherlands (1). Bulgaria reported 3 seizures that were en-route 
from Spain (1) and the Netherlands (1). The Czech Republic also reported 2 seizures, for which the 
final destination was Israel and 1 of the seizures occurred in Israel. 
In the cases where the origin of the seizures reported to the EMCDDA was known, the country of 
origin indicated was China (2). In a seizure made at Roissy Airport in France, the origin of the seizure 
was reported as China and the final destination was Austria. In a seizure made at Madrid-Barajas 
Airport in Spain, the origin was also reported as China and the final destination was France. 
The largest single seizure of AB-CHMINACA, which was in herbal form, was reported to the EMCDDA 
by Spain. In March 2016, in the frame of ‘Operation Alimaya’, a large scale operation carried out in 
Alicante, a total of 145,157 packages (of 1–3 g each, containing also AMB-FUB and AB-FUBINACA) 
and 2 bags (of 2 kg each, containing also AMB-FUB) were seized.  
F2. Impact on the production, trafficking and distribution of other substances, including 
existing psychoactive substances as well as new psychoactive substances 
No information was reported nor identified concerning the impact of AB-CHMINACA on the 
production, trafficking and distribution of other substances, including existing psychoactive 
substances as well as new psychoactive substances. 
F3. Evidence of the same groups of people being involved in different types of crime 
No information was reported nor identified concerning evidence of the same groups of people being 
involved in different types of crime related to the availability of AB-CHMINACA. 
F4. Impact of violence from criminal groups on society as a whole or on social groups or 
local communities (public order and safety) 
No information was reported nor identified concerning incidents of violence related to the availability 
of AB-CHMINACA.  
RISK ASSESSMENT I AB-CHMINACA  
 
53 
 
F5. Evidence of money laundering practices, or impact of organised crime on other 
socioeconomic factors in society 
No information was reported nor identified concerning evidence of money laundering practices, or 
impact of organised crime on other socioeconomic factors in society related to the availability of AB-
CHMINACA. 
F6. Economic costs and consequences (evasion of taxes or duties, costs to the judicial 
system)  
No information was reported nor identified concerning the economic costs and consequences related 
to the availability of AB-CHMINACA. 
F7. Use of violence between or within criminal groups 
No information was reported nor identified concerning the use of violence between or within criminal 
groups related to the availability of AB-CHMINACA. 
F8. Evidence of strategies to prevent prosecution, for example through corruption or 
intimidation 
No information was reported nor identified concerning evidence of strategies to prevent prosecution 
related to the availability of AB-CHMINACA. 
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